{"2f173fd2049daecd83183e243f2d61b44b39453b": [["Social workers and other gerontological scholars have increasingly voiced concern about loneliness (subjective perception of lack of meaningful relationships) and social isolation (social engagements and contacts) among older adults.", [["loneliness", "DISEASE", 88, 98]]], ["As key members of interprofessional geriatric teams, social workers are uniquely positioned to intervene in addressing social isolation by developing and testing interventions1.", [["social isolation", "TREATMENT", 119, 135], ["testing interventions", "TREATMENT", 154, 175]]], ["By 2017, calling it a \"loneliness epidemic\", U.S. Surgeon General Vivek Murthy proclaimed loneliness and social isolation among the world's older adult population was a global epidemic (2).", [["social isolation", "TREATMENT", 105, 121]]]], "43b4f27fbd1fb5b1a3207f01742f09b86da3af78": [["A 56-year-old male with a long history of gastroesophageal reflux disease, multi-vessel coronary artery disease, and ischemic cardiomyopathy with a left ventricular ejection fraction of 15%, underwent orthotopic cardiac transplantation.", [["gastroesophageal", "ANATOMY", 42, 58], ["multi-vessel coronary artery", "ANATOMY", 75, 103], ["left ventricular", "ANATOMY", 148, 164], ["cardiac", "ANATOMY", 212, 219], ["gastroesophageal reflux disease", "DISEASE", 42, 73], ["multi-vessel coronary artery disease", "DISEASE", 75, 111], ["ischemic cardiomyopathy", "DISEASE", 117, 140], ["male", "ORGANISM", 14, 18], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 88, 103], ["ventricular", "MULTI-TISSUE_STRUCTURE", 153, 164], ["cardiac", "ORGAN", 212, 219], ["gastroesophageal reflux disease", "PROBLEM", 42, 73], ["multi-vessel coronary artery disease", "PROBLEM", 75, 111], ["ischemic cardiomyopathy", "PROBLEM", 117, 140], ["a left ventricular ejection fraction", "TEST", 146, 182], ["orthotopic cardiac transplantation", "TREATMENT", 201, 235], ["gastroesophageal", "ANATOMY", 42, 58], ["reflux disease", "OBSERVATION", 59, 73], ["multi-vessel", "OBSERVATION", 75, 87], ["coronary artery", "ANATOMY", 88, 103], ["disease", "OBSERVATION", 104, 111], ["ischemic", "OBSERVATION_MODIFIER", 117, 125], ["cardiomyopathy", "OBSERVATION", 126, 140], ["left ventricular", "ANATOMY", 148, 164], ["ejection fraction", "OBSERVATION", 165, 182], ["cardiac", "ANATOMY", 212, 219], ["transplantation", "OBSERVATION", 220, 235]]], ["Eight weeks afterward, he developed multiple painful oral aphthous ulcers while receiving mycophenolate mofetil (MMF) 1000 mg twice a day, tacrolimus 3 mg twice a day, prednisone 30 mg once a day, aspirin 81 mg, and pantoprazole 40 mg once a day for \"gastric ulcer prophylaxis.\"", [["oral", "ANATOMY", 53, 57], ["gastric ulcer", "ANATOMY", 251, 264], ["aphthous ulcers", "DISEASE", 58, 73], ["mycophenolate mofetil", "CHEMICAL", 90, 111], ["MMF", "CHEMICAL", 113, 116], ["tacrolimus", "CHEMICAL", 139, 149], ["prednisone", "CHEMICAL", 168, 178], ["aspirin", "CHEMICAL", 197, 204], ["pantoprazole", "CHEMICAL", 216, 228], ["gastric ulcer", "DISEASE", 251, 264], ["mycophenolate mofetil", "CHEMICAL", 90, 111], ["MMF", "CHEMICAL", 113, 116], ["tacrolimus", "CHEMICAL", 139, 149], ["prednisone", "CHEMICAL", 168, 178], ["aspirin", "CHEMICAL", 197, 204], ["pantoprazole", "CHEMICAL", 216, 228], ["oral", "ORGANISM_SUBDIVISION", 53, 57], ["aphthous ulcers", "PATHOLOGICAL_FORMATION", 58, 73], ["mycophenolate mofetil", "SIMPLE_CHEMICAL", 90, 111], ["MMF", "SIMPLE_CHEMICAL", 113, 116], ["tacrolimus", "SIMPLE_CHEMICAL", 139, 149], ["prednisone", "SIMPLE_CHEMICAL", 168, 178], ["aspirin", "SIMPLE_CHEMICAL", 197, 204], ["pantoprazole", "SIMPLE_CHEMICAL", 216, 228], ["gastric", "ORGAN", 251, 258], ["ulcer", "PATHOLOGICAL_FORMATION", 259, 264], ["multiple painful oral aphthous ulcers", "PROBLEM", 36, 73], ["mycophenolate mofetil (MMF)", "TREATMENT", 90, 117], ["tacrolimus", "TREATMENT", 139, 149], ["prednisone", "TREATMENT", 168, 178], ["aspirin", "TREATMENT", 197, 204], ["pantoprazole", "TREATMENT", 216, 228], ["gastric ulcer prophylaxis", "TREATMENT", 251, 276], ["multiple", "OBSERVATION_MODIFIER", 36, 44], ["painful", "OBSERVATION_MODIFIER", 45, 52], ["oral", "ANATOMY", 53, 57], ["aphthous ulcers", "OBSERVATION", 58, 73], ["gastric", "ANATOMY", 251, 258], ["ulcer", "OBSERVATION", 259, 264]]], ["With aphthous ulcers and a mild leucopenia of 3100/\u00b5L (normal: 4000-11,000/\u00b5L), with an otherwise normal white cell differential count, MMF was reduced to 500 mg twice daily and prednisone to 20 mg daily, while continuing pantoprazole 40 mg daily, with oral lidocaine solution added as needed for symptom relief.", [["aphthous ulcers", "ANATOMY", 5, 20], ["white cell", "ANATOMY", 105, 115], ["oral", "ANATOMY", 253, 257], ["ulcers", "DISEASE", 14, 20], ["leucopenia", "DISEASE", 32, 42], ["MMF", "CHEMICAL", 136, 139], ["prednisone", "CHEMICAL", 178, 188], ["pantoprazole", "CHEMICAL", 222, 234], ["lidocaine", "CHEMICAL", 258, 267], ["MMF", "CHEMICAL", 136, 139], ["prednisone", "CHEMICAL", 178, 188], ["pantoprazole", "CHEMICAL", 222, 234], ["lidocaine", "CHEMICAL", 258, 267], ["aphthous ulcers", "PATHOLOGICAL_FORMATION", 5, 20], ["cell", "CELL", 111, 115], ["MMF", "SIMPLE_CHEMICAL", 136, 139], ["prednisone", "SIMPLE_CHEMICAL", 178, 188], ["pantoprazole", "SIMPLE_CHEMICAL", 222, 234], ["oral", "ORGANISM_SUBDIVISION", 253, 257], ["lidocaine", "SIMPLE_CHEMICAL", 258, 267], ["aphthous ulcers", "PROBLEM", 5, 20], ["a mild leucopenia", "PROBLEM", 25, 42], ["MMF", "TREATMENT", 136, 139], ["prednisone", "TREATMENT", 178, 188], ["pantoprazole", "TREATMENT", 222, 234], ["oral lidocaine solution", "TREATMENT", 253, 276], ["symptom relief", "PROBLEM", 297, 311], ["aphthous", "OBSERVATION_MODIFIER", 5, 13], ["ulcers", "OBSERVATION", 14, 20], ["mild", "OBSERVATION_MODIFIER", 27, 31], ["leucopenia", "OBSERVATION", 32, 42], ["white cell", "OBSERVATION_MODIFIER", 105, 115]]], ["Though the oral ulcers resolved within a few weeks, 12 weeks post-transplantation, he developed the rapid onset of epigastric pain after every meal, associated with nausea, vomiting, and a 20 lb. weight loss, the latter due to his oral intake being decreased for fear of aggravating the pain.", [["oral ulcers", "ANATOMY", 11, 22], ["epigastric", "ANATOMY", 115, 125], ["oral", "ANATOMY", 231, 235], ["ulcers", "DISEASE", 16, 22], ["epigastric pain", "DISEASE", 115, 130], ["nausea", "DISEASE", 165, 171], ["vomiting", "DISEASE", 173, 181], ["weight loss", "DISEASE", 196, 207], ["pain", "DISEASE", 287, 291], ["oral ulcers", "PATHOLOGICAL_FORMATION", 11, 22], ["epigastric", "ORGANISM_SUBDIVISION", 115, 125], ["oral", "ORGANISM_SUBDIVISION", 231, 235], ["the oral ulcers", "PROBLEM", 7, 22], ["epigastric pain", "PROBLEM", 115, 130], ["nausea", "PROBLEM", 165, 171], ["vomiting", "PROBLEM", 173, 181], ["weight loss", "PROBLEM", 196, 207], ["his oral intake", "PROBLEM", 227, 242], ["the pain", "PROBLEM", 283, 291], ["oral", "ANATOMY", 11, 15], ["ulcers", "OBSERVATION", 16, 22], ["rapid", "OBSERVATION_MODIFIER", 100, 105], ["epigastric", "ANATOMY", 115, 125], ["pain", "OBSERVATION", 126, 130], ["loss", "OBSERVATION", 203, 207]]], ["The dose of pantoprazole was increased to 40 mg b.i.d., and prednisone dose was decreased to 10 mg daily.", [["pantoprazole", "CHEMICAL", 12, 24], ["prednisone", "CHEMICAL", 60, 70], ["pantoprazole", "CHEMICAL", 12, 24], ["prednisone", "CHEMICAL", 60, 70], ["pantoprazole", "SIMPLE_CHEMICAL", 12, 24], ["prednisone", "SIMPLE_CHEMICAL", 60, 70], ["pantoprazole", "TREATMENT", 12, 24], ["prednisone dose", "TREATMENT", 60, 75]]], ["Despite these changes, epigastric pain continued and he was unable to tolerate an adequate oral intake.", [["epigastric", "ANATOMY", 23, 33], ["oral", "ANATOMY", 91, 95], ["epigastric pain", "DISEASE", 23, 38], ["epigastric", "ORGANISM_SUBDIVISION", 23, 33], ["oral", "ORGANISM_SUBDIVISION", 91, 95], ["epigastric pain", "PROBLEM", 23, 38], ["epigastric", "ANATOMY", 23, 33], ["pain", "OBSERVATION", 34, 38]]], ["A few weeks later, he was evaluated in the emergency department with melena, worsening epigastric pain, loss of appetite, and generalized weakness for 2 days.", [["epigastric", "ANATOMY", 87, 97], ["melena", "DISEASE", 69, 75], ["epigastric pain", "DISEASE", 87, 102], ["loss of appetite", "DISEASE", 104, 120], ["weakness", "DISEASE", 138, 146], ["epigastric", "ORGANISM_SUBDIVISION", 87, 97], ["melena", "PROBLEM", 69, 75], ["worsening epigastric pain", "PROBLEM", 77, 102], ["loss of appetite", "PROBLEM", 104, 120], ["generalized weakness", "PROBLEM", 126, 146], ["melena", "OBSERVATION", 69, 75], ["worsening", "OBSERVATION_MODIFIER", 77, 86], ["epigastric", "ANATOMY", 87, 97], ["pain", "OBSERVATION", 98, 102], ["generalized", "OBSERVATION_MODIFIER", 126, 137], ["weakness", "OBSERVATION", 138, 146]]], ["On examination, he appeared pale, with a blood pressure of 154/76 mm Hg, a heart rate of 108 beats/min, and epigastric tenderness on palpation, but with no signs of peritonitis, such as rebound tenderness, marked guarding or diffuse abdominal rigidity.", [["blood", "ANATOMY", 41, 46], ["heart", "ANATOMY", 75, 80], ["epigastric", "ANATOMY", 108, 118], ["abdominal", "ANATOMY", 233, 242], ["epigastric tenderness", "DISEASE", 108, 129], ["peritonitis", "DISEASE", 165, 176], ["tenderness", "DISEASE", 194, 204], ["abdominal rigidity", "DISEASE", 233, 251], ["Hg", "CHEMICAL", 69, 71], ["blood", "ORGANISM_SUBSTANCE", 41, 46], ["heart", "ORGAN", 75, 80], ["epigastric", "ORGANISM_SUBDIVISION", 108, 118], ["abdominal", "ORGANISM_SUBDIVISION", 233, 242], ["examination", "TEST", 3, 14], ["a blood pressure", "TEST", 39, 55], ["a heart rate", "TEST", 73, 85], ["epigastric tenderness", "PROBLEM", 108, 129], ["palpation", "TEST", 133, 142], ["peritonitis", "PROBLEM", 165, 176], ["rebound tenderness", "PROBLEM", 186, 204], ["marked guarding", "PROBLEM", 206, 221], ["diffuse abdominal rigidity", "PROBLEM", 225, 251], ["pale", "OBSERVATION", 28, 32], ["heart", "ANATOMY", 75, 80], ["epigastric", "ANATOMY", 108, 118], ["tenderness", "OBSERVATION", 119, 129], ["no signs of", "UNCERTAINTY", 153, 164], ["peritonitis", "OBSERVATION", 165, 176], ["rebound", "OBSERVATION_MODIFIER", 186, 193], ["marked", "OBSERVATION_MODIFIER", 206, 212], ["guarding", "OBSERVATION", 213, 221], ["diffuse", "OBSERVATION_MODIFIER", 225, 232], ["abdominal", "ANATOMY", 233, 242], ["rigidity", "OBSERVATION", 243, 251]]], ["Bowel sounds were normal.", [["Bowel", "ANATOMY", 0, 5], ["sounds", "OBSERVATION", 6, 12], ["normal", "OBSERVATION", 18, 24]]], ["Initial laboratory tests (with normal ranges) showed a blood hemoglobin of 9.6 g/dL, fallen from a baseline 2 weeks previously of 14.2 g/dL (13.5-17.7 g/dL), a mean corpuscular volume (MCV) 89 fL (80-100 fL), a red cell distribution width (RDW) of 13% (11-14.5%), a platelet count of 443,000/\u00b5L (150,000-400,000/\u00b5L), and a total white blood cell count (WBC) of 3000/\u00b5L (4000-11,000/ \u00b5L).", [["blood", "ANATOMY", 55, 60], ["corpuscular", "ANATOMY", 165, 176], ["red cell", "ANATOMY", 211, 219], ["platelet", "ANATOMY", 266, 274], ["white blood cell", "ANATOMY", 329, 345], ["blood", "ORGANISM_SUBSTANCE", 55, 60], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 61, 71], ["corpuscular", "TISSUE", 165, 176], ["red cell", "CELL", 211, 219], ["platelet", "CELL", 266, 274], ["white blood cell", "CELL", 329, 345], ["hemoglobin", "PROTEIN", 61, 71], ["Initial laboratory tests", "TEST", 0, 24], ["a blood hemoglobin", "TEST", 53, 71], ["dL", "TEST", 137, 139], ["a mean corpuscular volume", "TEST", 158, 183], ["MCV", "TEST", 185, 188], ["fL", "TEST", 193, 195], ["a red cell distribution width", "TEST", 209, 238], ["RDW", "TEST", 240, 243], ["a platelet count", "TEST", 264, 280], ["\u00b5L", "TEST", 292, 294], ["a total white blood cell count", "TEST", 321, 351], ["WBC", "TEST", 353, 356], ["red cell", "OBSERVATION", 211, 219], ["distribution", "OBSERVATION_MODIFIER", 220, 232], ["width", "OBSERVATION_MODIFIER", 233, 238]]], ["Iron profile showed serum iron of 28 ug/dl (65-170 ug/ dl), total iron binding capacity of 231 ug/dl (250-450 ug/dl), iron saturation of 12% (20-55% normal limits), and serum ferritin (non-fasting) of 2585 ng/ml (30-530 ng/ml).", [["serum", "ANATOMY", 20, 25], ["serum", "ANATOMY", 169, 174], ["Iron", "CHEMICAL", 0, 4], ["iron", "CHEMICAL", 26, 30], ["iron", "CHEMICAL", 66, 70], ["iron", "CHEMICAL", 118, 122], ["Iron", "CHEMICAL", 0, 4], ["iron", "CHEMICAL", 26, 30], ["iron", "CHEMICAL", 66, 70], ["iron", "CHEMICAL", 118, 122], ["Iron", "SIMPLE_CHEMICAL", 0, 4], ["serum", "ORGANISM_SUBSTANCE", 20, 25], ["iron", "SIMPLE_CHEMICAL", 26, 30], ["iron", "SIMPLE_CHEMICAL", 66, 70], ["iron", "SIMPLE_CHEMICAL", 118, 122], ["serum", "ORGANISM_SUBSTANCE", 169, 174], ["ferritin", "GENE_OR_GENE_PRODUCT", 175, 183], ["non-fasting", "ORGANISM_SUBSTANCE", 185, 196], ["serum ferritin", "PROTEIN", 169, 183], ["Iron profile", "TEST", 0, 12], ["serum iron", "TEST", 20, 30], ["dl", "TEST", 40, 42], ["total iron binding capacity", "TEST", 60, 87], ["dl", "TEST", 98, 100], ["iron saturation", "TEST", 118, 133], ["serum ferritin", "TEST", 169, 183]]], ["The low serum iron, low iron saturation, and thrombocytosis suggested the presence of iron deficiency anemia, despite the high serum ferritin which is as yet unexplained.", [["serum", "ANATOMY", 8, 13], ["serum", "ANATOMY", 127, 132], ["iron", "CHEMICAL", 14, 18], ["iron", "CHEMICAL", 24, 28], ["thrombocytosis", "DISEASE", 45, 59], ["iron", "CHEMICAL", 86, 90], ["anemia", "DISEASE", 102, 108], ["iron", "CHEMICAL", 14, 18], ["iron", "CHEMICAL", 24, 28], ["iron", "CHEMICAL", 86, 90], ["serum", "ORGANISM_SUBSTANCE", 8, 13], ["iron", "SIMPLE_CHEMICAL", 14, 18], ["iron", "SIMPLE_CHEMICAL", 24, 28], ["iron", "SIMPLE_CHEMICAL", 86, 90], ["serum", "ORGANISM_SUBSTANCE", 127, 132], ["ferritin", "GENE_OR_GENE_PRODUCT", 133, 141], ["serum ferritin", "PROTEIN", 127, 141], ["The low serum iron", "TEST", 0, 18], ["low iron saturation", "PROBLEM", 20, 39], ["thrombocytosis", "PROBLEM", 45, 59], ["iron deficiency anemia", "PROBLEM", 86, 108], ["the high serum ferritin", "PROBLEM", 118, 141], ["low", "OBSERVATION_MODIFIER", 4, 7], ["thrombocytosis", "OBSERVATION", 45, 59], ["iron deficiency anemia", "OBSERVATION", 86, 108]]], ["Other blood tests were all normal.", [["blood", "ANATOMY", 6, 11], ["blood", "ORGANISM_SUBSTANCE", 6, 11], ["Other blood tests", "TEST", 0, 17], ["normal", "OBSERVATION", 27, 33]]], ["Computerized tomographic angiography (CTA) scans of the abdomen and pelvis (with and without contrast) showed no occlusion within celiac or mesenteric vasculature, and the hepatobiliary system and spleen within normal limits.", [["abdomen", "ANATOMY", 56, 63], ["pelvis", "ANATOMY", 68, 74], ["celiac", "ANATOMY", 130, 136], ["mesenteric vasculature", "ANATOMY", 140, 162], ["hepatobiliary system", "ANATOMY", 172, 192], ["spleen", "ANATOMY", 197, 203], ["abdomen", "ORGAN", 56, 63], ["pelvis", "ORGAN", 68, 74], ["celiac", "MULTI-TISSUE_STRUCTURE", 130, 136], ["mesenteric vasculature", "MULTI-TISSUE_STRUCTURE", 140, 162], ["hepatobiliary system", "MULTI-TISSUE_STRUCTURE", 172, 192], ["spleen", "ORGAN", 197, 203], ["Computerized tomographic angiography (CTA) scans of the abdomen and pelvis (with and without contrast)", "TEST", 0, 102], ["occlusion within celiac or mesenteric vasculature", "PROBLEM", 113, 162], ["abdomen", "ANATOMY", 56, 63], ["pelvis", "ANATOMY", 68, 74], ["no", "UNCERTAINTY", 110, 112], ["occlusion", "OBSERVATION", 113, 122], ["celiac", "ANATOMY", 130, 136], ["mesenteric vasculature", "ANATOMY", 140, 162], ["hepatobiliary system", "ANATOMY", 172, 192], ["spleen", "ANATOMY", 197, 203], ["normal limits", "OBSERVATION", 211, 224]]], ["Promptly hospitalized, he underwent esophagogastroduodenoscopy (EGD).", [["esophagogastroduodenoscopy", "TEST", 36, 62], ["EGD", "TEST", 64, 67]]], ["While the esophagus was normal, EGD showed two large ulcer craters (1 cm and 5 cm, respectively) in the gastric antrum, with heaped up erythematous edges, and multiple (about 10), small (< 5 mm), non-bleeding aphthous ulcers in the corpus: No abnormality was seen in the duodenum.", [["esophagus", "ANATOMY", 10, 19], ["ulcer", "ANATOMY", 53, 58], ["gastric antrum", "ANATOMY", 104, 118], ["aphthous ulcers", "ANATOMY", 209, 224], ["corpus", "ANATOMY", 232, 238], ["duodenum", "ANATOMY", 271, 279], ["ulcer", "DISEASE", 53, 58], ["ulcers", "DISEASE", 218, 224], ["esophagus", "ORGAN", 10, 19], ["ulcer", "PATHOLOGICAL_FORMATION", 53, 58], ["gastric antrum", "MULTI-TISSUE_STRUCTURE", 104, 118], ["aphthous ulcers", "PATHOLOGICAL_FORMATION", 209, 224], ["corpus", "ORGAN", 232, 238], ["duodenum", "ORGAN", 271, 279], ["EGD", "TEST", 32, 35], ["two large ulcer craters", "PROBLEM", 43, 66], ["heaped up erythematous edges", "PROBLEM", 125, 153], ["small (< 5 mm), non-bleeding aphthous ulcers in the corpus", "PROBLEM", 180, 238], ["abnormality", "PROBLEM", 243, 254], ["esophagus", "ANATOMY", 10, 19], ["normal", "OBSERVATION", 24, 30], ["two", "OBSERVATION_MODIFIER", 43, 46], ["large", "OBSERVATION_MODIFIER", 47, 52], ["ulcer", "OBSERVATION", 53, 58], ["craters", "OBSERVATION_MODIFIER", 59, 66], ["1 cm", "OBSERVATION_MODIFIER", 68, 72], ["5 cm", "OBSERVATION_MODIFIER", 77, 81], ["gastric antrum", "ANATOMY", 104, 118], ["erythematous", "OBSERVATION_MODIFIER", 135, 147], ["edges", "OBSERVATION_MODIFIER", 148, 153], ["multiple", "OBSERVATION_MODIFIER", 159, 167], ["small", "OBSERVATION_MODIFIER", 180, 185], ["< 5 mm", "OBSERVATION_MODIFIER", 187, 193], ["non-bleeding", "OBSERVATION_MODIFIER", 196, 208], ["aphthous", "OBSERVATION_MODIFIER", 209, 217], ["ulcers", "OBSERVATION", 218, 224], ["corpus", "ANATOMY_MODIFIER", 232, 238], ["abnormality", "OBSERVATION", 243, 254], ["duodenum", "ANATOMY", 271, 279]]], ["Multiple biopsies were taken from the ulcer edges, with additional random biopsies from the adjacent gastric mucosa.", [["biopsies", "ANATOMY", 9, 17], ["ulcer", "ANATOMY", 38, 43], ["biopsies", "ANATOMY", 74, 82], ["gastric mucosa", "ANATOMY", 101, 115], ["ulcer", "DISEASE", 38, 43], ["biopsies", "CANCER", 9, 17], ["biopsies", "CANCER", 74, 82], ["gastric mucosa", "MULTI-TISSUE_STRUCTURE", 101, 115], ["Multiple biopsies", "TEST", 0, 17], ["the ulcer edges", "PROBLEM", 34, 49], ["additional random biopsies", "TEST", 56, 82], ["biopsies", "OBSERVATION", 9, 17], ["ulcer edges", "OBSERVATION", 38, 49], ["biopsies", "OBSERVATION", 74, 82], ["adjacent", "ANATOMY_MODIFIER", 92, 100], ["gastric mucosa", "ANATOMY", 101, 115]]], ["Histologic examination of these showed gastric antral and oxyntic mucosa with foci of erosion, and reactive foveolar hyperplasia.", [["gastric antral", "ANATOMY", 39, 53], ["oxyntic mucosa", "ANATOMY", 58, 72], ["foci", "ANATOMY", 78, 82], ["foveolar hyperplasia", "ANATOMY", 108, 128], ["erosion", "DISEASE", 86, 93], ["foveolar hyperplasia", "DISEASE", 108, 128], ["gastric antral", "MULTI-TISSUE_STRUCTURE", 39, 53], ["oxyntic mucosa", "MULTI-TISSUE_STRUCTURE", 58, 72], ["foveolar hyperplasia", "PATHOLOGICAL_FORMATION", 108, 128], ["Histologic examination", "TEST", 0, 22], ["gastric antral and oxyntic mucosa", "PROBLEM", 39, 72], ["erosion", "PROBLEM", 86, 93], ["reactive foveolar hyperplasia", "PROBLEM", 99, 128], ["gastric antral", "ANATOMY", 39, 53], ["oxyntic mucosa", "ANATOMY", 58, 72], ["foci", "OBSERVATION_MODIFIER", 78, 82], ["erosion", "OBSERVATION", 86, 93], ["reactive", "OBSERVATION_MODIFIER", 99, 107], ["foveolar hyperplasia", "OBSERVATION", 108, 128]]], ["Immunostains for CMV and Helicobacter pylori, and GMS stain for fungal elements were all negative; the biopsies showed no intestinal metaplasia, dysplasia, or malignant change.", [["biopsies", "ANATOMY", 103, 111], ["intestinal metaplasia", "ANATOMY", 122, 143], ["dysplasia", "ANATOMY", 145, 154], ["intestinal metaplasia", "DISEASE", 122, 143], ["dysplasia", "DISEASE", 145, 154], ["CMV", "ORGANISM", 17, 20], ["Helicobacter pylori", "ORGANISM", 25, 44], ["biopsies", "CANCER", 103, 111], ["intestinal metaplasia", "CANCER", 122, 143], ["dysplasia", "PATHOLOGICAL_FORMATION", 145, 154], ["Helicobacter pylori", "SPECIES", 25, 44], ["CMV", "SPECIES", 17, 20], ["Helicobacter pylori", "SPECIES", 25, 44], ["Immunostains", "TEST", 0, 12], ["CMV", "PROBLEM", 17, 20], ["Helicobacter pylori", "PROBLEM", 25, 44], ["GMS stain", "TEST", 50, 59], ["fungal elements", "PROBLEM", 64, 79], ["the biopsies", "TEST", 99, 111], ["intestinal metaplasia", "PROBLEM", 122, 143], ["dysplasia", "PROBLEM", 145, 154], ["malignant change", "PROBLEM", 159, 175], ["Helicobacter pylori", "OBSERVATION", 25, 44], ["no", "UNCERTAINTY", 119, 121], ["intestinal", "ANATOMY", 122, 132], ["metaplasia", "OBSERVATION", 133, 143], ["dysplasia", "OBSERVATION", 145, 154], ["malignant", "OBSERVATION", 159, 168]]], ["After consultation with the transplantation team and pathologist, the MMF was discontinued and the patient's therapy was changed to azathioprine with continuation of tacrolimus, prednisone, and pantoprazole.", [["MMF", "CHEMICAL", 70, 73], ["azathioprine", "CHEMICAL", 132, 144], ["tacrolimus", "CHEMICAL", 166, 176], ["prednisone", "CHEMICAL", 178, 188], ["pantoprazole", "CHEMICAL", 194, 206], ["MMF", "CHEMICAL", 70, 73], ["azathioprine", "CHEMICAL", 132, 144], ["tacrolimus", "CHEMICAL", 166, 176], ["prednisone", "CHEMICAL", 178, 188], ["pantoprazole", "CHEMICAL", 194, 206], ["MMF", "SIMPLE_CHEMICAL", 70, 73], ["patient", "ORGANISM", 99, 106], ["azathioprine", "SIMPLE_CHEMICAL", 132, 144], ["tacrolimus", "SIMPLE_CHEMICAL", 166, 176], ["prednisone", "SIMPLE_CHEMICAL", 178, 188], ["pantoprazole", "SIMPLE_CHEMICAL", 194, 206], ["patient", "SPECIES", 99, 106], ["the MMF", "TREATMENT", 66, 73], ["the patient's therapy", "TREATMENT", 95, 116], ["azathioprine", "TREATMENT", 132, 144], ["tacrolimus", "TREATMENT", 166, 176], ["prednisone", "TREATMENT", 178, 188], ["pantoprazole", "TREATMENT", 194, 206]]], ["Sucralfate solution 1 g four times a day was started.", [["Sucralfate", "CHEMICAL", 0, 10], ["Sucralfate", "CHEMICAL", 0, 10], ["Sucralfate", "SIMPLE_CHEMICAL", 0, 10], ["Sucralfate solution", "TREATMENT", 0, 19]]], ["A day after the EGD, he was able to tolerate a full liquid diet and was discharged home.", [["the EGD", "TEST", 12, 19], ["a full liquid diet", "TREATMENT", 45, 63]]]], "9eb098758c3b9a1d564c5ad805073455ee369659": [["Contents lists available at ScienceDirectTravel Medicine and Infectious Disease journal homepage: www.elsevier.com/locate/tmaidA pregnant woman with COVID-19 in Central AmericaDear Editor, Over the last three months, the pandemic of Coronavirus Disease 2019 (COVID-19) has caused significant concern in the world due to its rapid spreading [1, 2] .", [["Infectious Disease", "DISEASE", 61, 79], ["Coronavirus Disease", "DISEASE", 233, 252], ["COVID-19", "CHEMICAL", 259, 267], ["woman", "ORGANISM", 138, 143], ["woman", "SPECIES", 138, 143], ["Coronavirus Disease 2019 (COVID-19", "SPECIES", 233, 267], ["COVID", "TEST", 149, 154], ["Coronavirus Disease", "PROBLEM", 233, 252], ["its rapid spreading", "PROBLEM", 320, 339], ["Central", "ANATOMY_MODIFIER", 161, 168], ["Coronavirus Disease", "OBSERVATION", 233, 252], ["significant", "OBSERVATION_MODIFIER", 280, 291]]], ["However, there is still limited evidence of the full spectrum and impact of COVID-19 in certain population groups, including pregnant women [4] .", [["COVID-19", "CHEMICAL", 76, 84], ["women", "ORGANISM", 134, 139], ["women", "SPECIES", 134, 139], ["COVID", "TEST", 76, 81]]], ["No case reports on COVID-19 from Central America are yet available in scientific journals, including its occurrence during pregnancy.A pregnant woman with COVID-19 in Central AmericaOn March 9, 2020, a 41-year-old female, who was 31 weeks pregnant, with gestational hypertension and hypothyroidism, presented to the Hospital Escuela of Tegucigalpa, Honduras, with intermittent fever, dry cough, headache and myalgias for three days.", [["gestational hypertension", "DISEASE", 254, 278], ["hypothyroidism", "DISEASE", 283, 297], ["intermittent fever", "DISEASE", 364, 382], ["dry cough", "DISEASE", 384, 393], ["headache", "DISEASE", 395, 403], ["myalgias", "DISEASE", 408, 416], ["woman", "ORGANISM", 144, 149], ["female", "ORGANISM", 214, 220], ["woman", "SPECIES", 144, 149], ["COVID", "TEST", 19, 24], ["gestational hypertension", "PROBLEM", 254, 278], ["hypothyroidism", "PROBLEM", 283, 297], ["intermittent fever", "PROBLEM", 364, 382], ["dry cough", "PROBLEM", 384, 393], ["headache", "PROBLEM", 395, 403], ["myalgias", "PROBLEM", 408, 416], ["hypertension", "OBSERVATION", 266, 278], ["hypothyroidism", "OBSERVATION", 283, 297], ["intermittent", "OBSERVATION_MODIFIER", 364, 376], ["fever", "OBSERVATION", 377, 382], ["cough", "OBSERVATION", 388, 393]]], ["Her neighbours in Madrid were diagnosed with COVID-19.", [["COVID", "TEST", 45, 50]]], ["Therefore, given the patient's travel history and fever, a nasopharyngeal aspirate sample was collected and tested following WHO guidelines for real-time RT-PCR at the National Virology Laboratory of Tegucigalpa, following the protocol Charit\u00e9, Berlin, Germany [5] .", [["nasopharyngeal aspirate sample", "ANATOMY", 59, 89], ["fever", "DISEASE", 50, 55], ["patient", "ORGANISM", 21, 28], ["nasopharyngeal aspirate", "CANCER", 59, 82], ["patient", "SPECIES", 21, 28], ["fever", "PROBLEM", 50, 55], ["a nasopharyngeal aspirate sample", "TEST", 57, 89], ["nasopharyngeal", "ANATOMY", 59, 73]]], ["The results were positive, and then she went into isolation at the hospital.A pregnant woman with COVID-19 in Central AmericaOn admission, the physical examination revealed a body temperature of 36.0\u00b0C, high blood pressure (130/100 mmHg), normal pulse, and normal respiratory rate.", [["body", "ANATOMY", 175, 179], ["blood", "ANATOMY", 208, 213], ["respiratory", "ANATOMY", 264, 275], ["woman", "ORGANISM", 87, 92], ["body", "ORGANISM_SUBDIVISION", 175, 179], ["blood", "ORGANISM_SUBSTANCE", 208, 213], ["woman", "SPECIES", 87, 92], ["COVID", "TEST", 98, 103], ["the physical examination", "TEST", 139, 163], ["a body temperature", "TEST", 173, 191], ["high blood pressure", "TEST", 203, 222], ["positive", "OBSERVATION", 17, 25], ["normal", "OBSERVATION", 257, 263], ["respiratory rate", "OBSERVATION", 264, 280]]], ["She presented bilateral conjunctival hyperemia.", [["conjunctival", "ANATOMY", 24, 36], ["hyperemia", "DISEASE", 37, 46], ["conjunctival", "ORGAN", 24, 36], ["bilateral conjunctival hyperemia", "PROBLEM", 14, 46], ["bilateral", "ANATOMY_MODIFIER", 14, 23], ["conjunctival", "ANATOMY", 24, 36], ["hyperemia", "OBSERVATION", 37, 46]]], ["Lung auscultation revealed no alterations.", [["Lung", "ANATOMY", 0, 4], ["Lung", "ORGAN", 0, 4], ["Lung auscultation", "TEST", 0, 17], ["alterations", "PROBLEM", 30, 41], ["auscultation", "OBSERVATION", 5, 17], ["no", "UNCERTAINTY", 27, 29], ["alterations", "OBSERVATION", 30, 41]]], ["An obstetric ultrasound revealed a fetus with a dysplastic and multicystic right kidney with no other alterations.", [["fetus", "ANATOMY", 35, 40], ["multicystic right kidney", "ANATOMY", 63, 87], ["fetus", "ORGANISM", 35, 40], ["kidney", "ORGAN", 81, 87], ["An obstetric ultrasound", "TEST", 0, 23], ["a fetus", "PROBLEM", 33, 40], ["a dysplastic and multicystic right kidney", "PROBLEM", 46, 87], ["other alterations", "PROBLEM", 96, 113], ["fetus", "ANATOMY", 35, 40], ["dysplastic", "OBSERVATION", 48, 58], ["multicystic", "OBSERVATION", 63, 74], ["right", "ANATOMY_MODIFIER", 75, 80], ["kidney", "ANATOMY", 81, 87], ["no other", "UNCERTAINTY", 93, 101], ["alterations", "OBSERVATION", 102, 113]]], ["After ten days of hospitalization, she was stable, remaining under observation until delivery.", [["delivery", "TREATMENT", 85, 93], ["stable", "OBSERVATION_MODIFIER", 43, 49]]], ["On March 19, 2020, at week 32, occurred a preterm delivery, with a male newborn obtained by spontaneous vaginal delivery.", [["vaginal", "ANATOMY", 104, 111], ["newborn", "ORGANISM", 72, 79], ["vaginal", "ORGANISM_SUBDIVISION", 104, 111], ["spontaneous vaginal delivery", "TREATMENT", 92, 120]]], ["His birth weight was 1,500 grams.", [["His birth weight", "TEST", 0, 16]]], ["His nasopharyngeal and blood samples tested by SARS-CoV-2 rRT-PCR were negative.", [["nasopharyngeal", "ANATOMY", 4, 18], ["blood samples", "ANATOMY", 23, 36], ["nasopharyngeal", "CANCER", 4, 18], ["blood samples", "ORGANISM_SUBSTANCE", 23, 36], ["SARS-CoV-2 rRT", "DNA", 47, 61], ["His nasopharyngeal and blood samples", "TEST", 0, 36], ["SARS", "TEST", 47, 51], ["CoV", "TEST", 52, 55], ["PCR", "TEST", 62, 65], ["nasopharyngeal", "ANATOMY", 4, 18]]], ["He was hospitalized in the Hospital Maria of Pediatric Specialties, Tegucigalpa.", [["Tegucigalpa", "TREATMENT", 68, 79]]], ["The nasopharyngeal sample of the mother at delivery persisted positive at the SARS-CoV-2 rRT-PCR.", [["nasopharyngeal sample", "ANATOMY", 4, 25], ["nasopharyngeal sample", "CANCER", 4, 25], ["mother", "ORGANISM", 33, 39], ["SARS-CoV-2 rRT-PCR", "DNA", 78, 96], ["positive", "PROBLEM", 62, 70], ["the SARS", "TEST", 74, 82], ["CoV", "TEST", 83, 86], ["nasopharyngeal", "ANATOMY", 4, 18]]], ["She remains asymptomatic.A pregnant woman with COVID-19 in Central AmericaAccording to previous reports for SARS in pregnancy in Hong Kong, SARS-CoV infection could be associated with poor pregnancy outcomes, including critical maternal illness, spontaneous abortion, or maternal death, preterm birth [6, 7] .", [["SARS", "DISEASE", 108, 112], ["SARS-CoV infection", "DISEASE", 140, 158], ["maternal illness", "DISEASE", 228, 244], ["spontaneous abortion", "DISEASE", 246, 266], ["death", "DISEASE", 280, 285], ["preterm birth", "DISEASE", 287, 300], ["woman", "ORGANISM", 36, 41], ["SARS-CoV", "ORGANISM", 140, 148], ["woman", "SPECIES", 36, 41], ["SARS-CoV", "SPECIES", 140, 148], ["asymptomatic", "PROBLEM", 12, 24], ["COVID", "TEST", 47, 52], ["SARS in pregnancy", "PROBLEM", 108, 125], ["SARS", "PROBLEM", 140, 144], ["CoV infection", "PROBLEM", 145, 158], ["poor pregnancy outcomes", "PROBLEM", 184, 207], ["critical maternal illness", "PROBLEM", 219, 244], ["spontaneous abortion", "PROBLEM", 246, 266], ["maternal death", "PROBLEM", 271, 285], ["asymptomatic", "OBSERVATION", 12, 24], ["infection", "OBSERVATION", 149, 158]]], ["In this case, her clinical presentation showed no significant alterations related to COVID-19, as has also been reported recently in a case in China, except for the preterm delivery [6] .A pregnant woman with COVID-19 in Central AmericaSo far, there is currently no evidence for intrauterine infection caused by vertical transmission in women who develop COVID-19 pneumonia in late pregnancy [4] .", [["intrauterine", "ANATOMY", 279, 291], ["intrauterine infection", "DISEASE", 279, 301], ["pneumonia", "DISEASE", 364, 373], ["woman", "ORGANISM", 198, 203], ["intrauterine", "IMMATERIAL_ANATOMICAL_ENTITY", 279, 291], ["women", "ORGANISM", 337, 342], ["COVID-19", "DNA", 85, 93], ["woman", "SPECIES", 198, 203], ["women", "SPECIES", 337, 342], ["significant alterations", "PROBLEM", 50, 73], ["COVID", "TEST", 85, 90], ["the preterm delivery", "TREATMENT", 161, 181], ["COVID", "TEST", 209, 214], ["intrauterine infection", "PROBLEM", 279, 301], ["COVID", "TEST", 355, 360], ["pneumonia in late pregnancy", "PROBLEM", 364, 391], ["no", "UNCERTAINTY", 47, 49], ["significant", "OBSERVATION_MODIFIER", 50, 61], ["alterations", "OBSERVATION", 62, 73], ["no evidence for", "UNCERTAINTY", 263, 278], ["infection", "OBSERVATION", 292, 301], ["pneumonia", "OBSERVATION", 364, 373]]], ["A recent study confirmed that the outcomes of patients who were infected in late pregnancy appeared very good [8] .", [["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["A recent study", "TEST", 0, 14], ["infected", "OBSERVATION", 64, 72]]], ["Nevertheless, this implies the need to further assessment, with rRT-PCR, after delivery, as we expect to perform in a few weeks in this case.", [["further assessment", "TEST", 39, 57], ["rRT-PCR", "TEST", 64, 71], ["delivery", "TREATMENT", 79, 87]]], ["Pregnant women are particularly susceptible to respiratory pathogens and severe pneumonia because of their physiological adaptive changes (e.g., diaphragm elevation, increased oxygen consumption, and oedema of respiratory tract mucosa) and immunosuppressive state.", [["respiratory", "ANATOMY", 47, 58], ["diaphragm", "ANATOMY", 145, 154], ["respiratory tract mucosa", "ANATOMY", 210, 234], ["respiratory pathogens", "DISEASE", 47, 68], ["pneumonia", "DISEASE", 80, 89], ["oxygen", "CHEMICAL", 176, 182], ["oedema", "DISEASE", 200, 206], ["oxygen", "CHEMICAL", 176, 182], ["women", "ORGANISM", 9, 14], ["diaphragm", "MULTI-TISSUE_STRUCTURE", 145, 154], ["oxygen", "SIMPLE_CHEMICAL", 176, 182], ["respiratory tract", "ORGANISM_SUBDIVISION", 210, 227], ["mucosa", "MULTI-TISSUE_STRUCTURE", 228, 234], ["women", "SPECIES", 9, 14], ["respiratory pathogens", "PROBLEM", 47, 68], ["severe pneumonia", "PROBLEM", 73, 89], ["their physiological adaptive changes", "PROBLEM", 101, 137], ["diaphragm elevation", "PROBLEM", 145, 164], ["increased oxygen consumption", "PROBLEM", 166, 194], ["oedema of respiratory tract mucosa", "PROBLEM", 200, 234], ["immunosuppressive state", "PROBLEM", 240, 263], ["severe", "OBSERVATION_MODIFIER", 73, 79], ["pneumonia", "OBSERVATION", 80, 89], ["physiological adaptive", "OBSERVATION", 107, 129], ["diaphragm", "ANATOMY", 145, 154], ["elevation", "OBSERVATION", 155, 164], ["increased", "OBSERVATION_MODIFIER", 166, 175], ["oxygen consumption", "OBSERVATION", 176, 194], ["respiratory tract", "ANATOMY", 210, 227], ["immunosuppressive state", "OBSERVATION", 240, 263]]], ["With the increase of the pandemic in Latin America, a region with high fecundity rates, we should expect to see more cases of COVID-19 among pregnant women that need to be studied in detail to understand better its clinical impact.Declaration of competing interestAuthors declare no conflict of interest.", [["women", "ORGANISM", 150, 155], ["women", "SPECIES", 150, 155], ["high fecundity rates", "PROBLEM", 66, 86], ["COVID", "TEST", 126, 131], ["increase", "OBSERVATION_MODIFIER", 9, 17], ["pandemic", "OBSERVATION_MODIFIER", 25, 33], ["high fecundity", "OBSERVATION", 66, 80]]]], "03b283d2b7ca915dfb36797868fa229539d8ea25": [["SARS-Cov-2 and COVID-19 a new pandemic.", [["SARS", "DISEASE", 0, 4], ["SARS", "TEST", 0, 4], ["Cov", "TEST", 5, 8], ["COVID", "TEST", 15, 20], ["new", "OBSERVATION_MODIFIER", 26, 29], ["pandemic", "OBSERVATION", 30, 38]]], ["COVID-19 is the pandemic disease caused by severe acute respiratory syndrome (SARS) coronavirus two (SARS-CoV-2) infection Zhou et al. 2020) .", [["COVID-19", "CHEMICAL", 0, 8], ["pandemic disease", "DISEASE", 16, 32], ["acute respiratory syndrome (SARS) coronavirus", "DISEASE", 50, 95], ["infection", "DISEASE", 113, 122], ["severe acute respiratory syndrome (SARS) coronavirus", "SPECIES", 43, 95], ["COVID", "TEST", 0, 5], ["the pandemic disease", "PROBLEM", 12, 32], ["severe acute respiratory syndrome", "PROBLEM", 43, 76], ["SARS) coronavirus two (SARS-CoV", "PROBLEM", 78, 109], ["infection", "PROBLEM", 113, 122], ["pandemic disease", "OBSERVATION", 16, 32], ["severe", "OBSERVATION_MODIFIER", 43, 49], ["acute", "OBSERVATION_MODIFIER", 50, 55], ["respiratory syndrome", "OBSERVATION", 56, 76]]], ["About 80% of people infected with SARS-CoV-2 develop a selflimiting illness, 20% require hospitalisation, largely due to cardiovascular issues and about 5% require critical care and potential ventilatory support (Kimball et al. 2020; Day.", [["cardiovascular", "ANATOMY", 121, 135], ["SARS", "DISEASE", 34, 38], ["selflimiting illness", "DISEASE", 55, 75], ["people", "ORGANISM", 13, 19], ["SARS-CoV-2", "ORGANISM", 34, 44], ["people", "SPECIES", 13, 19], ["SARS-CoV", "SPECIES", 34, 42], ["SARS", "PROBLEM", 34, 38], ["a selflimiting illness", "PROBLEM", 53, 75], ["cardiovascular issues", "PROBLEM", 121, 142], ["critical care", "TREATMENT", 164, 177], ["potential ventilatory support", "TREATMENT", 182, 211]]], ["The mortality in those requiring ventilatory support is about 40-50% (Weiss & Murdoch 2020; Zhu et al. 2020b) .", [["ventilatory support", "TREATMENT", 33, 52]]], ["Death from COVID-19 is associated with older age and comorbidities such as cardiovascular disease, smoking, lung disease, obesity and diabetes Lippi et al. 2020; Richardson et al. 2020) .", [["cardiovascular", "ANATOMY", 75, 89], ["lung", "ANATOMY", 108, 112], ["Death", "DISEASE", 0, 5], ["cardiovascular disease", "DISEASE", 75, 97], ["lung disease", "DISEASE", 108, 120], ["obesity", "DISEASE", 122, 129], ["diabetes", "DISEASE", 134, 142], ["lung", "ORGAN", 108, 112], ["Death", "PROBLEM", 0, 5], ["comorbidities", "PROBLEM", 53, 66], ["cardiovascular disease", "PROBLEM", 75, 97], ["lung disease", "PROBLEM", 108, 120], ["obesity", "PROBLEM", 122, 129], ["diabetes", "PROBLEM", 134, 142], ["cardiovascular", "ANATOMY", 75, 89], ["disease", "OBSERVATION", 90, 97], ["lung", "ANATOMY", 108, 112], ["disease", "OBSERVATION", 113, 120], ["obesity", "OBSERVATION", 122, 129]]], ["Mortality in young people and those without comorbidities may be related to excessive viral load (Lui et al 2020a; Chen et al. 2020a) .", [["people", "ORGANISM", 19, 25], ["people", "SPECIES", 19, 25], ["comorbidities", "PROBLEM", 44, 57], ["excessive viral load", "PROBLEM", 76, 96]]], ["Whilst the typical clinical features requiring self-isolation, and potentially hospitalization are fever, dry cough and shortness of breath related to respiratory tract infection, other symptoms such as headache and gastrointestinal symptoms may go unnoticed or under-appreciated leading to spreading of the virus (Zhu et al. 2020b; Richardson et al. 2020; Huang et al. 2020) .", [["respiratory tract", "ANATOMY", 151, 168], ["gastrointestinal", "ANATOMY", 216, 232], ["fever", "DISEASE", 99, 104], ["dry cough", "DISEASE", 106, 115], ["shortness of breath", "DISEASE", 120, 139], ["respiratory tract infection", "DISEASE", 151, 178], ["headache", "DISEASE", 203, 211], ["gastrointestinal symptoms", "DISEASE", 216, 241], ["tract", "ORGANISM_SUBDIVISION", 163, 168], ["gastrointestinal", "ORGAN", 216, 232], ["self-isolation", "TREATMENT", 47, 61], ["fever", "PROBLEM", 99, 104], ["dry cough", "PROBLEM", 106, 115], ["shortness of breath", "PROBLEM", 120, 139], ["respiratory tract infection", "PROBLEM", 151, 178], ["other symptoms", "PROBLEM", 180, 194], ["headache", "PROBLEM", 203, 211], ["gastrointestinal symptoms", "PROBLEM", 216, 241], ["respiratory tract", "ANATOMY", 151, 168], ["infection", "OBSERVATION", 169, 178], ["gastrointestinal", "ANATOMY", 216, 232]]], ["People shed infective virus days before symptoms occur and continue to shed virus via the lungs and faeces whilst symptoms develop and resolve, often for more than 7 days after symptom onset (Lauer et al. 2020; Xu et al. 2020a; He et al.2020a ).", [["lungs", "ANATOMY", 90, 95], ["faeces", "ANATOMY", 100, 106], ["People", "ORGANISM", 0, 6], ["lungs", "ORGAN", 90, 95], ["faeces", "ORGANISM_SUBSTANCE", 100, 106], ["People", "SPECIES", 0, 6], ["symptoms", "PROBLEM", 40, 48], ["symptoms", "PROBLEM", 114, 122], ["lungs", "ANATOMY", 90, 95]]]], "800c9aec07afc773936d60a24d766559c9b71e2b": [["The ongoing pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), referred to as coronavirus disease 2019 , has caused over 13 million infections and over 560,000 deaths worldwide (https://www. who.int/emergencies/diseases/novel-coronavirus-2019/sit uation-reports), posing a significant threat to globally public health and economics.", [["acute respiratory syndrome coronavirus", "DISEASE", 31, 69], ["coronavirus disease", "DISEASE", 101, 120], ["infections", "DISEASE", 155, 165], ["deaths", "DISEASE", 183, 189], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 24, 71], ["SARS-CoV-2", "ORGANISM", 73, 83], ["coronavirus", "ORGANISM", 249, 260], ["severe acute respiratory syndrome coronavirus", "SPECIES", 24, 69], ["SARS-CoV-2", "SPECIES", 73, 83], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 24, 69], ["diseases", "PROBLEM", 234, 242], ["coronavirus", "PROBLEM", 249, 260], ["severe", "OBSERVATION_MODIFIER", 24, 30], ["acute", "OBSERVATION_MODIFIER", 31, 36], ["respiratory syndrome", "OBSERVATION", 37, 57]]], ["At present, no efficacious antiviral drugs and vaccines have been approved for the prophylaxis or treatment of COVID-19.", [["efficacious antiviral drugs", "TREATMENT", 15, 42], ["vaccines", "TREATMENT", 47, 55], ["the prophylaxis", "TREATMENT", 79, 94], ["treatment", "TREATMENT", 98, 107], ["COVID", "TEST", 111, 116], ["no", "UNCERTAINTY", 12, 14], ["efficacious", "OBSERVATION_MODIFIER", 15, 26], ["antiviral drugs", "OBSERVATION", 27, 42]]], ["Tremendous efforts have been made to develop drug and vaccine against SARS-CoV-2.", [["SARS", "DISEASE", 70, 74], ["SARS-CoV-2", "ORGANISM", 70, 80], ["SARS-CoV", "SPECIES", 70, 78], ["drug and vaccine", "TREATMENT", 45, 61], ["SARS", "PROBLEM", 70, 74]]], ["The main protease (Mpro, also called 3CLpro) is an attractive drug target among coronaviruses, and several potent inhibitors of the SARS-CoV-2 3CLpro together with their crystal structures in complex with the protease have been reported (Dai et al., 2020; Jin et al., 2020; Zhang et al., 2020) .", [["Mpro", "GENE_OR_GENE_PRODUCT", 19, 23], ["3CLpro", "GENE_OR_GENE_PRODUCT", 37, 43], ["coronaviruses", "ORGANISM", 80, 93], ["SARS-CoV-2 3CLpro", "ORGANISM", 132, 149], ["protease", "PROTEIN", 9, 17], ["Mpro", "PROTEIN", 19, 23], ["3CLpro", "PROTEIN", 37, 43], ["SARS-CoV-2 3CLpro", "DNA", 132, 149], ["protease", "PROTEIN", 209, 217], ["coronaviruses", "PROBLEM", 80, 93], ["several potent inhibitors", "TREATMENT", 99, 124], ["the SARS", "TEST", 128, 136], ["CoV-2 3CLpro", "TREATMENT", 137, 149], ["the protease", "TREATMENT", 205, 217], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["While the viral RNA-dependent RNA polymerases (RdRp) are well-known broad-spectrum antiviral drug targets, the cryo-electron microscopy structures of the SARS-CoV-2 RdRp and its complex with remdesivir, a promising antiviral candidate developed by Gilead Sciences, validated the efficient inhibition of the viral RNA replication by remdesivir and provided a rational template for drug design to combat SARS-CoV-2 infections Wang et al., 2020; Yin et al., 2020) .", [["SARS", "DISEASE", 154, 158], ["remdesivir", "CHEMICAL", 191, 201], ["remdesivir", "CHEMICAL", 332, 342], ["SARS", "DISEASE", 402, 406], ["infections", "DISEASE", 413, 423], ["remdesivir", "CHEMICAL", 191, 201], ["RNA-dependent RNA polymerases", "GENE_OR_GENE_PRODUCT", 16, 45], ["SARS-CoV-2", "ORGANISM", 154, 164], ["RdRp", "ORGANISM", 165, 169], ["remdesivir", "SIMPLE_CHEMICAL", 191, 201], ["remdesivir", "SIMPLE_CHEMICAL", 332, 342], ["viral RNA-dependent RNA polymerases", "PROTEIN", 10, 45], ["RdRp", "PROTEIN", 47, 51], ["SARS-CoV-2 RdRp", "PROTEIN", 154, 169], ["SARS-CoV-2 RdRp", "SPECIES", 154, 169], ["the viral RNA", "TEST", 6, 19], ["dependent RNA polymerases (RdRp", "PROBLEM", 20, 51], ["broad-spectrum antiviral drug targets", "TREATMENT", 68, 105], ["the cryo-electron microscopy", "TEST", 107, 135], ["the SARS", "TEST", 150, 158], ["CoV", "TEST", 159, 162], ["RdRp", "PROBLEM", 165, 169], ["remdesivir", "TREATMENT", 191, 201], ["the viral RNA replication", "TREATMENT", 303, 328], ["a rational template", "TREATMENT", 356, 375], ["SARS", "PROBLEM", 402, 406], ["viral RNA", "OBSERVATION", 10, 19], ["RNA polymerases", "OBSERVATION", 30, 45]]], ["In addition, the trimeric spike protein on the surface of SARS-CoV-2 plays a pivotal role during the viral entry by binding to the peptidase domain of angiotensin-converting enzyme 2 (ACE2), a host cell receptor .", [["surface", "ANATOMY", 47, 54], ["cell", "ANATOMY", 198, 202], ["angiotensin", "CHEMICAL", 151, 162], ["surface", "CELLULAR_COMPONENT", 47, 54], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 58, 68], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 151, 182], ["ACE2", "GENE_OR_GENE_PRODUCT", 184, 188], ["host cell receptor", "GENE_OR_GENE_PRODUCT", 193, 211], ["trimeric spike protein", "PROTEIN", 17, 39], ["peptidase domain", "PROTEIN", 131, 147], ["angiotensin-converting enzyme 2", "PROTEIN", 151, 182], ["ACE2", "PROTEIN", 184, 188], ["host cell receptor", "PROTEIN", 193, 211], ["the trimeric spike protein", "PROBLEM", 13, 39], ["SARS", "TEST", 58, 62], ["CoV", "TEST", 63, 66], ["angiotensin", "TEST", 151, 162], ["a host cell receptor", "TREATMENT", 191, 211], ["host cell", "OBSERVATION", 193, 202]]], ["It has been revealed that not only the receptor binding domain which is recognized by ACE2 but also the N-terminal domain of the SARS-CoV-2 spike protein is targeting sites for therapeutic monoclonal antibodies (Chi et al., 2020) .", [["N", "CHEMICAL", 104, 105], ["ACE2", "GENE_OR_GENE_PRODUCT", 86, 90], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 129, 139], ["receptor binding domain", "PROTEIN", 39, 62], ["ACE2", "PROTEIN", 86, 90], ["N-terminal domain", "PROTEIN", 104, 121], ["SARS-CoV-2 spike protein", "PROTEIN", 129, 153], ["therapeutic monoclonal antibodies", "PROTEIN", 177, 210], ["ACE2", "TEST", 86, 90], ["the SARS", "TEST", 125, 133], ["CoV", "TEST", 134, 137], ["therapeutic monoclonal antibodies", "PROBLEM", 177, 210]]], ["Accordingly, both the inhibitors of 3CLpro or RdRp and the antibodies targeting the spike protein provide potential candidates for development of the direct-acting antiviral (DAA) drugs for the treatment of COVID-19.", [["3CLpro", "GENE_OR_GENE_PRODUCT", 36, 42], ["RdRp", "GENE_OR_GENE_PRODUCT", 46, 50], ["DAA", "SIMPLE_CHEMICAL", 175, 178], ["3CLpro", "PROTEIN", 36, 42], ["RdRp", "PROTEIN", 46, 50], ["antibodies", "PROTEIN", 59, 69], ["spike protein", "PROTEIN", 84, 97], ["the inhibitors", "TREATMENT", 18, 32], ["3CLpro", "TREATMENT", 36, 42], ["RdRp", "TREATMENT", 46, 50], ["the antibodies", "TREATMENT", 55, 69], ["the direct-acting antiviral (DAA) drugs", "TREATMENT", 146, 185], ["COVID", "TEST", 207, 212]]]], "ce4252922cce80f4284eae7607b1967b35596ef5": [["The P4 (forward: 5'-TTGTGTGTGGTCAAGGAGACGG-3') and P5 specific primers were designed to amplify the full-length double-stranded cDNA (2319 bp) with the Expand High Fidelity PCR System kit, according to manufacturer's instructions (Roche Applied Science, France).", [["full-length double-stranded cDNA", "DNA", 100, 132], ["2319 bp", "DNA", 134, 141], ["TTGTGTGTGGTCAAGGAGACGG", "TEST", 20, 42], ["bp", "TEST", 139, 141]]], ["Six Supplementary sets of specific primers were used to amplify (products from 371 to 594 bp) and to sequence DNAI1 cDNA (primer sequences available upon request).", [["DNAI1 cDNA", "DNA", 110, 120], ["primer sequences", "DNA", 122, 138], ["specific primers", "TREATMENT", 26, 42], ["bp", "TEST", 90, 92]]], ["Purified PCR products were sequenced using the Big Dye \u00ae sequencing chemistry (Applied Biosystems, Foster City, CA).", [["Purified PCR products", "TREATMENT", 0, 21], ["the Big Dye", "TREATMENT", 43, 54]]], ["Full-length DNAI1 cDNA PCR product was cloned into pCR \u00ae II-TOPO \u00ae vector and used to transform DH5\u03b1 One Shot competent cells, according to the manufacturer's protocol (Invitrogen).", [["cells", "ANATOMY", 120, 125], ["DH5\u03b1", "CHEMICAL", 96, 100], ["DNAI1", "GENE_OR_GENE_PRODUCT", 12, 17], ["cells", "CELL", 120, 125], ["pCR \u00ae II-TOPO \u00ae vector", "DNA", 51, 73], ["DH5", "DNA", 96, 99], ["Shot competent cells", "CELL_LINE", 105, 125], ["Full-length DNAI1 cDNA PCR product", "TREATMENT", 0, 34], ["TOPO \u00ae vector", "TREATMENT", 60, 73], ["the manufacturer's protocol", "TREATMENT", 140, 167]]], ["Cloned products were sequenced as previously described.", [["Cloned products", "TREATMENT", 0, 15]]]], "186b2401c4247a4b2f4026090e6112204faa106d": [["During a pandemic about which too little is known, public health is facing a crisis on multiple levels, including regarding COVID-19 related-health messaging.", [["a crisis", "PROBLEM", 75, 83], ["COVID", "TEST", 124, 129]]], ["With the federal government's inadequate, inconsistent and largely nonevidence-based response [1] [2] [3] , and the far reach of social media \"armchair experts\" [4, 5] , tremendous uncertainty, fear, and anger has emerged with respect to the origins, treatments and prevention methods regarding COVID-19.", [["treatments", "TREATMENT", 251, 261], ["COVID", "TEST", 295, 300]]], ["Disinformation (strategically and deliberately spread false information), misinformation (false information, not necessarily with intent to mislead), and mistrust (more than the lack of trust; suspicion of ill intent) are multi-faceted phenomena, with heterogeneous underlying motivating factors.", [["multi-faceted phenomena", "PROBLEM", 222, 245], ["heterogeneous", "OBSERVATION_MODIFIER", 252, 265]]], ["The purpose of this commentary is to suggest that understanding the etiologies of disinformation, misinformation, and medical mistrust must be an important component of the public health response to COVID-19.", [["disinformation", "DISEASE", 82, 96], ["COVID-19", "CHEMICAL", 199, 207], ["COVID-19", "DNA", 199, 207], ["disinformation", "PROBLEM", 82, 96], ["COVID", "TEST", 199, 204]]], ["This is especially critical when considering how the pandemic has affected communities of color, including Asian communities who have been blamed for the introduction of SARS-CoV-2 to the U.S. [8, 9] and Black communities who have been blamed for higher fatality rates among Black populations [10] .", [["SARS", "DISEASE", 170, 174]]], ["We propose that two main forms of pushback against dominant scientific evidence have become prominent during COVID-19: (1) disinformation propagated at the institutional/federal government level to preserve power and undermine already marginalized groups, and (2) inequality-driven mistrust among communities that have been made vulnerable by historical and ongoing structural inequities.", [["prominent", "OBSERVATION_MODIFIER", 92, 101]]]], "2d002c963e61172843a7af5c0c4376a8c85962a2": [["Diejenigen, die keine Maske im Freien tragen, haben solche Masken sicher in der Tasche, denn ohne diese kommt man in kein Gesch\u00e4ft und keine Bahn.", [["man", "SPECIES", 110, 113]]], ["Treten sie aus dem Gesch\u00e4ft, wird die Maske abgenommen und wieder in die Tasche gesteckt.", [["Treten sie aus dem Gesch\u00e4ft, wird die Maske abgenommen und wieder", "SPECIES", 0, 65]]]], "PMC7140232": [["Der Test k\u00f6nnte vor allem Krankenh\u00e4user im Winter entlasten, wenn Grippewellen durch das Land ziehen. \u201eWenn wir Stationen schlie\u00dfen m\u00fcssen, weil Patienten mit ansteckenden viralen Atemwegsinfektionen aufgenommen wurden, die wir nicht antibiotisch behandeln k\u00f6nnen, dann ist das teuer und erh\u00f6ht den Druck auf das Krankenhaus.", [["Der Test", "TEST", 0, 8]]], ["Dies zu vermeiden sowie dem Patienten unn\u00f6tige Krankenhausaufenthalte und Antibiotika-Kuren zu ersparen w\u00e4re ein echter Fortschritt\u201c, kommentierte Prof. Tobias Welte von der Medizinischen Hochschule in Hannover und n\u00e4chster Pr\u00e4sident der European Respiratory Society (ERS).", [["Dies zu vermeiden sowie dem Patienten unn\u00f6tige Krankenhausaufenthalte und Antibiotika-Kuren zu ersparen w\u00e4re ein echter", "SPECIES", 0, 119]]]], "PMC4766433": [["Prevalence of SIVs with truncated or full-length PA-X ::: ResultsTo explore the relationship between truncation of PA-X and viral adaptation in swine, we analyzed the frequency of the PA-X truncations in SIV by year based on all SIV sequences available in the National Center for Biotechnology Information (NCBI) Influenza Viruses Resource, regardless of subtype and lineage.", [["Influenza Viruses", "DISEASE", 313, 330], ["SIVs", "CANCER", 14, 18], ["PA-X", "GENE_OR_GENE_PRODUCT", 115, 119], ["swine", "ORGANISM", 144, 149], ["PA-X", "GENE_OR_GENE_PRODUCT", 184, 188], ["SIV", "ORGANISM", 204, 207], ["SIV", "ORGANISM", 229, 232], ["PA-X truncations", "DNA", 184, 200], ["SIV sequences", "DNA", 229, 242], ["swine", "SPECIES", 144, 149], ["swine", "SPECIES", 144, 149], ["SIV", "SPECIES", 204, 207], ["SIV", "SPECIES", 229, 232], ["PA", "TEST", 115, 117], ["the PA-X truncations", "TREATMENT", 180, 200], ["all SIV sequences", "TEST", 225, 242], ["Influenza Viruses", "PROBLEM", 313, 330]]], ["As shown in Fig. 1, the PA-X proteins in all SIV cases were full-length before 1985, following which the number of SIVs containing truncated PA-X gradually increased.", [["PA-X", "GENE_OR_GENE_PRODUCT", 24, 28], ["SIV", "ORGANISM", 45, 48], ["PA-X", "GENE_OR_GENE_PRODUCT", 141, 145], ["PA-X proteins", "PROTEIN", 24, 37], ["SIVs", "PROTEIN", 115, 119], ["truncated PA-X", "PROTEIN", 131, 145], ["the PA", "TEST", 20, 26], ["increased", "OBSERVATION_MODIFIER", 156, 165]]], ["By 2015, more than 90% SIVs possessed truncated forms of PA-X.", [["SIVs", "CANCER", 23, 27], ["PA-X.", "GENE_OR_GENE_PRODUCT", 57, 62]]], ["These data suggested that the truncation of PA-X protein may play an important role in the adaptation of SIV in pigs.Generation of recombinant SIVs with truncated or full-length PA-X ::: ResultsTo investigate the effect of the length of PA-X on these biological properties, a reverse genetics system of wild type TR H1N2 SIV A/swine/Guangdong/1222/2006 [Sw-41X(WT)] possessing 41 amino acids in the X domain of PA-X was established as previously described10.", [["amino acids", "CHEMICAL", 380, 391], ["amino acids", "CHEMICAL", 380, 391], ["PA-X", "GENE_OR_GENE_PRODUCT", 44, 48], ["SIV", "ORGANISM", 105, 108], ["pigs", "ORGANISM", 112, 116], ["SIVs", "GENE_OR_GENE_PRODUCT", 143, 147], ["PA-X", "GENE_OR_GENE_PRODUCT", 237, 241], ["wild type TR H1N2 SIV A/swine", "ORGANISM", 303, 332], ["Guangdong/1222/2006", "ORGANISM", 333, 352], ["Sw-41X(WT)", "ORGANISM", 354, 364], ["amino acids", "AMINO_ACID", 380, 391], ["PA-X", "GENE_OR_GENE_PRODUCT", 411, 415], ["PA-X protein", "PROTEIN", 44, 56], ["recombinant SIVs", "PROTEIN", 131, 147], ["X domain", "PROTEIN", 399, 407], ["X", "PROTEIN", 414, 415], ["pigs", "SPECIES", 112, 116], ["H1N2 SIV", "SPECIES", 316, 324], ["swine", "SPECIES", 327, 332], ["SIV", "SPECIES", 105, 108], ["pigs", "SPECIES", 112, 116], ["SIV A/swine/Guangdong/1222/2006 [Sw-41X(WT)", "SPECIES", 321, 364], ["PA-X protein", "TREATMENT", 44, 56], ["possessing 41 amino acids", "TREATMENT", 366, 391], ["the X domain of PA", "TREATMENT", 395, 413]]], ["Meanwhile, the X-ORF of Sw-41X(WT) virus was extended to the full-length 61 amino acids X domain by substituting the stop codon to tryptophan at the 42nd amino acid position in X-ORF without altering PA ORF (Fig. 2).", [["Sw-41X", "CHEMICAL", 24, 30], ["amino acids", "CHEMICAL", 76, 87], ["tryptophan", "CHEMICAL", 131, 141], ["amino acid", "CHEMICAL", 154, 164], ["amino acids", "CHEMICAL", 76, 87], ["tryptophan", "CHEMICAL", 131, 141], ["amino acid", "CHEMICAL", 154, 164], ["Sw-41X(WT) virus", "ORGANISM", 24, 40], ["amino acids", "AMINO_ACID", 76, 87], ["tryptophan", "AMINO_ACID", 131, 141], ["amino acid", "AMINO_ACID", 154, 164], ["PA", "GENE_OR_GENE_PRODUCT", 200, 202], ["X-ORF", "DNA", 15, 20], ["full-length 61 amino acids X domain", "PROTEIN", 61, 96], ["42nd amino acid position", "PROTEIN", 149, 173], ["X-ORF", "DNA", 177, 182], ["PA ORF", "DNA", 200, 206], ["Sw-41X(WT) virus", "SPECIES", 24, 40], ["amino acids X domain", "TREATMENT", 76, 96], ["tryptophan", "TREATMENT", 131, 141], ["the 42nd amino acid position", "TREATMENT", 145, 173], ["altering PA ORF", "PROBLEM", 191, 206]]], ["This PA-X-extended H1N2 virus was named Sw-61X.In vitro properties of SIVs with truncated or full-length PA-X ::: ResultsThe influence of the length of PA-X on the replicative ability of H1N2 SIV in vitro was evaluated by inoculating porcine kidney (PK15) cells with each virus at a multiplicity of infection (MOI) of 0.01 in the presence of 1 \u03bcg/ml tosylsulfonyl phenylalanyl chloromethyl ketone-treated trypsin.", [["kidney (PK15) cells", "ANATOMY", 242, 261], ["Sw-61X", "CHEMICAL", 40, 46], ["infection", "DISEASE", 299, 308], ["tosylsulfonyl phenylalanyl chloromethyl ketone", "CHEMICAL", 350, 396], ["tosylsulfonyl phenylalanyl chloromethyl ketone", "CHEMICAL", 350, 396], ["PA", "GENE_OR_GENE_PRODUCT", 5, 7], ["H1N2 virus", "ORGANISM", 19, 29], ["Sw-61X", "GENE_OR_GENE_PRODUCT", 40, 46], ["SIVs", "CANCER", 70, 74], ["PA-X", "GENE_OR_GENE_PRODUCT", 152, 156], ["H1N2 SIV", "ORGANISM", 187, 195], ["porcine", "ORGANISM", 234, 241], ["kidney", "ORGAN", 242, 248], ["PK15) cells", "CELL", 250, 261], ["tosylsulfonyl phenylalanyl chloromethyl ketone", "SIMPLE_CHEMICAL", 350, 396], ["trypsin", "GENE_OR_GENE_PRODUCT", 405, 412], ["porcine kidney (PK15) cells", "CELL_LINE", 234, 261], ["trypsin", "PROTEIN", 405, 412], ["H1N2 virus", "SPECIES", 19, 29], ["H1N2 SIV", "SPECIES", 187, 195], ["porcine", "SPECIES", 234, 241], ["H1N2 virus", "SPECIES", 19, 29], ["Sw-61X", "SPECIES", 40, 46], ["H1N2 SIV", "SPECIES", 187, 195], ["porcine", "SPECIES", 234, 241], ["This PA", "TEST", 0, 7], ["X-extended H1N2 virus", "PROBLEM", 8, 29], ["H1N2 SIV", "TREATMENT", 187, 195], ["each virus", "PROBLEM", 267, 277], ["infection", "PROBLEM", 299, 308], ["tosylsulfonyl phenylalanyl chloromethyl ketone", "TREATMENT", 350, 396], ["kidney", "ANATOMY", 242, 248], ["infection", "OBSERVATION", 299, 308]]], ["As shown in Fig. 3A, the virus titers of Sw-41X(WT) were significantly higher than Sw-61X at 24 and 36 hours post-inoculation (hpi) (P < 0.05).In vitro properties of SIVs with truncated or full-length PA-X ::: ResultsAn ex vivo organ-culture model of the pig respiratory tract maintained at an air-liquid interface as a biologically relevant in vitro system was also used to study the replication of PA-X mutants as previously described11.", [["organ", "ANATOMY", 228, 233], ["respiratory tract", "ANATOMY", 259, 276], ["3A", "GENE_OR_GENE_PRODUCT", 17, 19], ["Sw-41X(WT)", "ORGANISM", 41, 51], ["Sw-61X", "CELL", 83, 89], ["SIVs", "CANCER", 166, 170], ["pig", "ORGANISM", 255, 258], ["respiratory tract", "ORGANISM_SUBDIVISION", 259, 276], ["PA-X", "GENE_OR_GENE_PRODUCT", 400, 404], ["pig", "SPECIES", 255, 258], ["Sw-41X", "SPECIES", 41, 47], ["Sw-61X", "SPECIES", 83, 89], ["pig", "SPECIES", 255, 258], ["the virus titers", "TEST", 21, 37], ["Sw", "TEST", 41, 43], ["An ex vivo organ", "TEST", 217, 233], ["culture", "TEST", 234, 241], ["the pig respiratory tract", "TREATMENT", 251, 276], ["PA-X mutants", "TREATMENT", 400, 412], ["Fig", "OBSERVATION", 12, 15], ["ex", "OBSERVATION", 220, 222], ["respiratory tract", "ANATOMY", 259, 276], ["air-liquid", "OBSERVATION", 294, 304]]], ["Briefly, porcine nasal turbinate, trachea, and lung explants cultured in 12-well plates were inoculated with 106 TCID50 of each virus, and virus titers in supernatants were subsequently tested at 24, 48, and 72 hpi.", [["nasal turbinate", "ANATOMY", 17, 32], ["trachea", "ANATOMY", 34, 41], ["lung explants", "ANATOMY", 47, 60], ["supernatants", "ANATOMY", 155, 167], ["porcine", "ORGANISM", 9, 16], ["nasal turbinate", "MULTI-TISSUE_STRUCTURE", 17, 32], ["trachea", "MULTI-TISSUE_STRUCTURE", 34, 41], ["lung explants", "CELL", 47, 60], ["porcine", "SPECIES", 9, 16], ["porcine nasal turbinate", "TREATMENT", 9, 32], ["trachea, and lung explants", "PROBLEM", 34, 60], ["each virus", "PROBLEM", 123, 133], ["virus titers", "TEST", 139, 151], ["nasal turbinate", "ANATOMY", 17, 32], ["trachea", "ANATOMY", 34, 41], ["lung", "ANATOMY", 47, 51], ["explants", "OBSERVATION", 52, 60]]], ["Sw-41X(WT) replicated more efficiently than Sw-61X in the explants of nasal turbinate at all three time points, and of trachea and lung at 48 hpi (P < 0.05) (Fig. 3B\u2013D).", [["explants", "ANATOMY", 58, 66], ["nasal turbinate", "ANATOMY", 70, 85], ["trachea", "ANATOMY", 119, 126], ["lung", "ANATOMY", 131, 135], ["Sw-61X", "CHEMICAL", 44, 50], ["Sw-61X", "CHEMICAL", 44, 50], ["Sw-41X", "GENE_OR_GENE_PRODUCT", 0, 6], ["Sw-61X", "GENE_OR_GENE_PRODUCT", 44, 50], ["explants", "DEVELOPING_ANATOMICAL_STRUCTURE", 58, 66], ["nasal turbinate", "MULTI-TISSUE_STRUCTURE", 70, 85], ["trachea", "MULTI-TISSUE_STRUCTURE", 119, 126], ["lung", "ORGAN", 131, 135], ["nasal turbinate", "PROBLEM", 70, 85], ["nasal turbinate", "ANATOMY", 70, 85], ["trachea", "ANATOMY", 119, 126], ["lung", "ANATOMY", 131, 135]]], ["Collected, these data indicated that truncation of PA-X promoted viral production in porcine cells or swine respiratory tissues infected ex vivo.Pathogenicity and transmissibility of SIVs with truncated or full-length PA-X in pigs ::: ResultsTo determine whether truncation of PA-X influenced the pathogenicity and transmissibility of SIV in pigs, nine four-week-old landrace specific-pathogen-free piglets obtained from Beijing Center for SPF Swine Breeding & Management of each group were inoculated intranasally with 106 TCID50 of each virus, and three infected pigs from each group were removed to a separate room with three na\u00efve pigs at 24 hpi.", [["cells", "ANATOMY", 93, 98], ["respiratory tissues", "ANATOMY", 108, 127], ["intranasally", "ANATOMY", 502, 514], ["PA-X", "GENE_OR_GENE_PRODUCT", 51, 55], ["porcine", "ORGANISM", 85, 92], ["cells", "CELL", 93, 98], ["swine", "ORGANISM", 102, 107], ["respiratory tissues", "TISSUE", 108, 127], ["SIVs", "CANCER", 183, 187], ["PA-X", "GENE_OR_GENE_PRODUCT", 218, 222], ["pigs", "ORGANISM", 226, 230], ["PA-X", "GENE_OR_GENE_PRODUCT", 277, 281], ["SIV", "ORGANISM", 335, 338], ["pigs", "ORGANISM", 342, 346], ["piglets", "ORGANISM", 399, 406], ["pigs", "ORGANISM", 565, 569], ["pigs", "ORGANISM", 635, 639], ["X", "DNA", 54, 55], ["porcine cells", "CELL_TYPE", 85, 98], ["truncated or full-length PA-X", "DNA", 193, 222], ["PA-X", "DNA", 277, 281], ["porcine", "SPECIES", 85, 92], ["swine", "SPECIES", 102, 107], ["pigs", "SPECIES", 226, 230], ["pigs", "SPECIES", 342, 346], ["piglets", "SPECIES", 399, 406], ["Swine", "SPECIES", 444, 449], ["pigs", "SPECIES", 565, 569], ["pigs", "SPECIES", 635, 639], ["porcine", "SPECIES", 85, 92], ["swine", "SPECIES", 102, 107], ["SIV", "SPECIES", 335, 338], ["pigs", "SPECIES", 342, 346], ["pigs", "SPECIES", 565, 569], ["pigs", "SPECIES", 635, 639], ["these data", "TEST", 11, 21], ["truncation of PA", "PROBLEM", 37, 53], ["viral production in porcine cells", "TREATMENT", 65, 98], ["swine respiratory tissues", "PROBLEM", 102, 127], ["Pathogenicity", "PROBLEM", 145, 158], ["transmissibility of SIVs", "PROBLEM", 163, 187], ["truncation of PA", "PROBLEM", 263, 279], ["the pathogenicity", "PROBLEM", 293, 310], ["SIV", "PROBLEM", 335, 338], ["pathogen", "PROBLEM", 385, 393], ["SPF Swine Breeding", "TREATMENT", 440, 458], ["Management of each group", "TREATMENT", 461, 485], ["each virus", "PROBLEM", 534, 544], ["porcine cells", "OBSERVATION", 85, 98], ["respiratory tissues", "OBSERVATION", 108, 127]]], ["The nasal turbinates, tracheas, and bronchoalveolar lavage fluids (BALFs) from three pigs in each inoculated group were collected for virus detection at 3 and 5 dpi.", [["nasal turbinates", "ANATOMY", 4, 20], ["tracheas", "ANATOMY", 22, 30], ["bronchoalveolar lavage fluids", "ANATOMY", 36, 65], ["BALFs", "ANATOMY", 67, 72], ["nasal turbinates", "MULTI-TISSUE_STRUCTURE", 4, 20], ["tracheas", "MULTI-TISSUE_STRUCTURE", 22, 30], ["bronchoalveolar lavage fluids", "ORGANISM_SUBSTANCE", 36, 65], ["BALFs", "CANCER", 67, 72], ["pigs", "ORGANISM", 85, 89], ["pigs", "SPECIES", 85, 89], ["pigs", "SPECIES", 85, 89], ["The nasal turbinates", "PROBLEM", 0, 20], ["tracheas", "TREATMENT", 22, 30], ["bronchoalveolar lavage fluids (BALFs", "TREATMENT", 36, 72], ["virus detection", "TEST", 134, 149], ["nasal turbinates", "ANATOMY", 4, 20], ["tracheas", "ANATOMY", 22, 30], ["bronchoalveolar lavage", "OBSERVATION", 36, 58]]], ["Clinical signs of the remaining three pigs were monitored daily throughout the duration of the study, and the nasal washes were collected at 3, 5, 7, and 9 days post-inoculation (dpi).", [["nasal", "ANATOMY", 110, 115], ["pigs", "ORGANISM", 38, 42], ["pigs", "SPECIES", 38, 42], ["Clinical signs", "TEST", 0, 14], ["the study", "TEST", 91, 100], ["the nasal washes", "TREATMENT", 106, 122], ["nasal", "ANATOMY", 110, 115], ["washes", "OBSERVATION", 116, 122]]], ["Five na\u00efve pigs were maintained as a control group and were mock-inoculated with 2 ml PBS, per nostril.Pathogenicity and transmissibility of SIVs with truncated or full-length PA-X in pigs ::: ResultsAs shown in Fig. 4A, the mean rectal temperature in pigs inoculated with Sw-41X(WT) was significantly higher than that in Sw-61X infected pigs during 1 to 3 dpi (P < 0.05).", [["rectal", "ANATOMY", 230, 236], ["Sw-41X", "CHEMICAL", 273, 279], ["pigs", "ORGANISM", 11, 15], ["nostril", "ORGANISM_SUBDIVISION", 95, 102], ["SIVs", "CANCER", 141, 145], ["PA-X", "GENE_OR_GENE_PRODUCT", 176, 180], ["pigs", "ORGANISM", 184, 188], ["rectal", "ORGANISM_SUBDIVISION", 230, 236], ["pigs", "ORGANISM", 252, 256], ["Sw-41X(WT)", "ORGANISM", 273, 283], ["Sw-61X", "CELL", 322, 328], ["pigs", "ORGANISM", 338, 342], ["truncated or full-length PA-X", "DNA", 151, 180], ["pigs", "SPECIES", 11, 15], ["pigs", "SPECIES", 184, 188], ["pigs", "SPECIES", 252, 256], ["pigs", "SPECIES", 338, 342], ["pigs", "SPECIES", 11, 15], ["pigs", "SPECIES", 252, 256], ["Sw-41X", "SPECIES", 273, 279], ["Sw-61X", "SPECIES", 322, 328], ["pigs", "SPECIES", 338, 342], ["Five na\u00efve pigs", "TREATMENT", 0, 15], ["Pathogenicity", "PROBLEM", 103, 116], ["transmissibility of SIVs", "PROBLEM", 121, 145], ["the mean rectal temperature", "TEST", 221, 248], ["Sw", "TEST", 273, 275], ["nostril", "ANATOMY", 95, 102]]], ["Sw-41X(WT) caused lethargy and lack of appetite in two of three inoculated animals during 1 to 3 dpi, and nasal secretion and coughing were observed in one of them at 2 dpi.", [["nasal", "ANATOMY", 106, 111], ["Sw-41X", "CHEMICAL", 0, 6], ["lethargy", "DISEASE", 18, 26], ["Sw-41X", "GENE_OR_GENE_PRODUCT", 0, 6], ["nasal", "ORGANISM_SUBDIVISION", 106, 111], ["lethargy", "PROBLEM", 18, 26], ["lack of appetite", "PROBLEM", 31, 47], ["nasal secretion", "PROBLEM", 106, 121], ["coughing", "PROBLEM", 126, 134], ["nasal", "ANATOMY", 106, 111], ["secretion", "OBSERVATION", 112, 121], ["coughing", "OBSERVATION", 126, 134]]], ["By contrast, infection with Sw-61X only produced slight lethargy and lack of appetite at 2 dpi in one infected animal.", [["infection", "DISEASE", 13, 22], ["Sw-61X", "CHEMICAL", 28, 34], ["lethargy", "DISEASE", 56, 64], ["Sw-61X", "CHEMICAL", 28, 34], ["Sw-61X", "SIMPLE_CHEMICAL", 28, 34], ["Sw-61X", "SPECIES", 28, 34], ["infection", "PROBLEM", 13, 22], ["slight lethargy", "PROBLEM", 49, 64], ["lack of appetite", "PROBLEM", 69, 85], ["infection", "OBSERVATION", 13, 22], ["slight", "OBSERVATION_MODIFIER", 49, 55], ["lethargy", "OBSERVATION", 56, 64], ["infected", "OBSERVATION", 102, 110]]], ["The virus titers of Sw-41X(WT) in nasal washes were significantly higher than Sw-61X at 3, 5 and 7 dpi (P < 0.05) (Fig. 4B,C).", [["nasal", "ANATOMY", 34, 39], ["Sw-41X", "CHEMICAL", 20, 26], ["Sw-41X(WT", "ORGANISM", 20, 29], ["nasal", "ORGAN", 34, 39], ["Sw-41X", "SPECIES", 20, 26], ["Sw-61X", "SPECIES", 78, 84], ["The virus titers", "TEST", 0, 16], ["Sw", "TEST", 20, 22], ["nasal washes", "TEST", 34, 46], ["virus", "OBSERVATION", 4, 9], ["nasal", "ANATOMY", 34, 39]]], ["Furthermore, pigs infected with Sw-41X(WT) virus shed the virus for much longer than Sw-61X virus.", [["Sw-41X", "CHEMICAL", 32, 38], ["pigs", "ORGANISM", 13, 17], ["Sw-41X(WT) virus", "ORGANISM", 32, 48], ["Sw-61X virus", "ORGANISM", 85, 97], ["pigs", "SPECIES", 13, 17], ["pigs", "SPECIES", 13, 17], ["Sw-41X", "SPECIES", 32, 38], ["Sw-61X virus", "SPECIES", 85, 97], ["Sw", "TEST", 32, 34], ["the virus", "PROBLEM", 54, 63]]], ["At 7 dpi, Sw-41X(WT) was still detectable in two of three pigs with virus titers of 104.5 TCID50/ml and 103.5 TCID50/ml, respectively, but none in Sw-61X group had detectable virus by that time (Fig. 4BC).", [["Sw-61X", "CHEMICAL", 147, 153], ["Sw-41X", "GENE_OR_GENE_PRODUCT", 10, 16], ["pigs", "ORGANISM", 58, 62], ["Sw-61X", "SIMPLE_CHEMICAL", 147, 153], ["pigs", "SPECIES", 58, 62], ["pigs", "SPECIES", 58, 62], ["virus titers", "TEST", 68, 80], ["detectable virus", "PROBLEM", 164, 180]]], ["For the contacted animals, viral shedding was detectable in all the pigs co-housed with Sw-41X(WT) with titers of 3.5 \u00b1 0.3 TCID50/ml and 1.9 \u00b1 0.3 TCID50/ml at 2 and 4 days post-contact (dpc), respectively; while virus was only detectable in two of three pigs in Sw-61X group at 2 dpc with titers of 101.8 TCID50/ml (Fig. 4BC).", [["Sw-41X", "CHEMICAL", 88, 94], ["Sw-61X", "CHEMICAL", 264, 270], ["pigs", "ORGANISM", 68, 72], ["Sw-41X(WT)", "ORGANISM", 88, 98], ["pigs", "ORGANISM", 256, 260], ["Sw-61X", "SIMPLE_CHEMICAL", 264, 270], ["dpc", "ORGAN", 282, 285], ["pigs", "SPECIES", 68, 72], ["pigs", "SPECIES", 256, 260], ["pigs", "SPECIES", 68, 72], ["Sw-41X", "SPECIES", 88, 94], ["pigs", "SPECIES", 256, 260], ["viral shedding", "PROBLEM", 27, 41], ["titers", "TEST", 104, 110], ["virus", "PROBLEM", 214, 219], ["titers", "TEST", 291, 297]]], ["Seroconversion was only detected in animals with viral shedding.", [["Seroconversion", "TREATMENT", 0, 14], ["viral shedding", "PROBLEM", 49, 63]]], ["Overall, SIV with truncated PA-X had increased pathogenicity and transmissibility compared with that with full-length PA-X.Histopathology and immunohistochemistry of swine lungs infected by PA-X mutant viruses ::: ResultsTo further examine viral pathology, three pigs from the infection group and one pig from the control group were anesthetized and their lungs were collected for evaluation of histopathology (H&E) and immunohistochemistry (IHC) at 5 dpi.", [["lungs", "ANATOMY", 172, 177], ["lungs", "ANATOMY", 356, 361], ["lungs infected", "DISEASE", 172, 186], ["infection", "DISEASE", 277, 286], ["SIV", "ORGANISM", 9, 12], ["PA-X", "GENE_OR_GENE_PRODUCT", 28, 32], ["swine", "ORGANISM", 166, 171], ["lungs", "ORGAN", 172, 177], ["PA-X mutant viruses", "ORGANISM", 190, 209], ["pigs", "ORGANISM", 263, 267], ["pig", "ORGANISM", 301, 304], ["lungs", "ORGAN", 356, 361], ["truncated PA-X", "DNA", 18, 32], ["swine", "SPECIES", 166, 171], ["pigs", "SPECIES", 263, 267], ["pig", "SPECIES", 301, 304], ["SIV", "SPECIES", 9, 12], ["swine", "SPECIES", 166, 171], ["pigs", "SPECIES", 263, 267], ["pig", "SPECIES", 301, 304], ["increased pathogenicity", "PROBLEM", 37, 60], ["Histopathology", "TEST", 123, 137], ["viral pathology", "TEST", 240, 255], ["the infection group", "TREATMENT", 273, 292], ["evaluation", "TEST", 381, 391], ["histopathology", "TEST", 395, 409], ["immunohistochemistry", "TEST", 420, 440], ["SIV", "OBSERVATION", 9, 12], ["increased", "OBSERVATION_MODIFIER", 37, 46], ["pathogenicity", "OBSERVATION", 47, 60], ["lungs", "ANATOMY", 172, 177], ["infected", "OBSERVATION", 178, 186], ["infection", "OBSERVATION", 277, 286], ["lungs", "ANATOMY", 356, 361]]], ["Histopathological analysis showed that the Sw-41X(WT) virus caused moderate bronchopneumonia and consolidation as characterized by local edema, dropout of epithelial cells in bronchia, and infiltration of inflammatory cells; while only mild bronchopneumonia was observed for pigs infected by Sw-61X (Fig. 5A).", [["epithelial cells", "ANATOMY", 155, 171], ["bronchia", "ANATOMY", 175, 183], ["inflammatory cells", "ANATOMY", 205, 223], ["bronchopneumonia", "DISEASE", 76, 92], ["edema", "DISEASE", 137, 142], ["bronchopneumonia", "DISEASE", 241, 257], ["Sw-61X", "CHEMICAL", 292, 298], ["Sw-41X(WT) virus", "ORGANISM", 43, 59], ["edema", "PATHOLOGICAL_FORMATION", 137, 142], ["epithelial cells", "CELL", 155, 171], ["bronchia", "CANCER", 175, 183], ["inflammatory cells", "CELL", 205, 223], ["pigs", "ORGANISM", 275, 279], ["Sw-61X", "ORGANISM", 292, 298], ["Fig. 5A", "ORGANISM", 300, 307], ["epithelial cells", "CELL_TYPE", 155, 171], ["inflammatory cells", "CELL_TYPE", 205, 223], ["pigs", "SPECIES", 275, 279], ["Sw-41X(WT) virus", "SPECIES", 43, 59], ["pigs", "SPECIES", 275, 279], ["Sw-61X", "SPECIES", 292, 298], ["Histopathological analysis", "TEST", 0, 26], ["the Sw", "TEST", 39, 45], ["virus", "PROBLEM", 54, 59], ["moderate bronchopneumonia", "PROBLEM", 67, 92], ["consolidation", "PROBLEM", 97, 110], ["local edema", "PROBLEM", 131, 142], ["epithelial cells in bronchia", "PROBLEM", 155, 183], ["infiltration of inflammatory cells", "PROBLEM", 189, 223], ["mild bronchopneumonia", "PROBLEM", 236, 257], ["moderate", "OBSERVATION_MODIFIER", 67, 75], ["bronchopneumonia", "OBSERVATION", 76, 92], ["consolidation", "OBSERVATION", 97, 110], ["local", "OBSERVATION_MODIFIER", 131, 136], ["edema", "OBSERVATION", 137, 142], ["epithelial cells", "OBSERVATION", 155, 171], ["bronchia", "ANATOMY", 175, 183], ["infiltration", "OBSERVATION_MODIFIER", 189, 201], ["inflammatory cells", "OBSERVATION", 205, 223], ["mild", "OBSERVATION_MODIFIER", 236, 240], ["bronchopneumonia", "OBSERVATION", 241, 257]]], ["Compared to Sw-61X, pigs exposed to Sw-41X(WT) showed increased SIV-positive signals in lungs (Fig. 5A).", [["lungs", "ANATOMY", 88, 93], ["Sw-61X", "CHEMICAL", 12, 18], ["Sw-41X", "CHEMICAL", 36, 42], ["Sw-61X", "GENE_OR_GENE_PRODUCT", 12, 18], ["pigs", "ORGANISM", 20, 24], ["Sw-41X", "ORGANISM", 36, 42], ["SIV", "ORGANISM", 64, 67], ["lungs", "ORGAN", 88, 93], ["pigs", "SPECIES", 20, 24], ["Sw-61X", "SPECIES", 12, 18], ["pigs", "SPECIES", 20, 24], ["Sw-41X", "SPECIES", 36, 42], ["increased SIV-positive signals in lungs", "PROBLEM", 54, 93], ["increased", "OBSERVATION_MODIFIER", 54, 63], ["SIV", "OBSERVATION", 64, 67], ["positive signals", "OBSERVATION", 68, 84], ["lungs", "ANATOMY", 88, 93]]], ["The average histopathological and immunohistochemical scores in the Sw-41X(WT) infected group were significantly higher than that of Sw-61X infected groups at 5 dpi (P < 0.05) (Fig. 5BC).", [["Sw-41X(WT", "ORGANISM", 68, 77], ["Sw-61X", "CELL", 133, 139], ["immunohistochemical scores", "TEST", 34, 60], ["the Sw", "TEST", 64, 70], ["Sw", "TEST", 133, 135]]], ["No microscopic lesions and SIV-positive signals were observed in the lungs of control pigs (Fig. 5BC).", [["lesions", "ANATOMY", 15, 22], ["lungs", "ANATOMY", 69, 74], ["lesions", "PATHOLOGICAL_FORMATION", 15, 22], ["SIV", "ORGANISM", 27, 30], ["lungs", "ORGAN", 69, 74], ["pigs", "ORGANISM", 86, 90], ["pigs", "SPECIES", 86, 90], ["SIV", "SPECIES", 27, 30], ["pigs", "SPECIES", 86, 90], ["microscopic lesions", "PROBLEM", 3, 22], ["SIV-positive signals", "PROBLEM", 27, 47], ["microscopic", "OBSERVATION_MODIFIER", 3, 14], ["lesions", "OBSERVATION", 15, 22], ["SIV", "OBSERVATION_MODIFIER", 27, 30], ["positive signals", "OBSERVATION", 31, 47], ["lungs", "ANATOMY", 69, 74]]], ["Taken together, the above results further demonstrated that truncated PA-X increased the pathogenicity of SIV in pigs.Replication of PA-X mutant SIVs in pigs ::: ResultsPathogenicity experiments in pigs demonstrated that SIV with truncated PA-X presented higher pathogenicity than full-length PA-X SIV.", [["PA-X", "GENE_OR_GENE_PRODUCT", 70, 74], ["SIV", "ORGANISM", 106, 109], ["pigs", "ORGANISM", 113, 117], ["PA-X", "GENE_OR_GENE_PRODUCT", 133, 137], ["pigs", "ORGANISM", 153, 157], ["pigs", "ORGANISM", 198, 202], ["SIV", "ORGANISM", 221, 224], ["PA-X", "GENE_OR_GENE_PRODUCT", 240, 244], ["PA-X SIV", "ORGANISM", 293, 301], ["truncated PA-X", "PROTEIN", 60, 74], ["truncated PA-X", "DNA", 230, 244], ["pigs", "SPECIES", 113, 117], ["pigs", "SPECIES", 153, 157], ["pigs", "SPECIES", 198, 202], ["SIV", "SPECIES", 106, 109], ["pigs", "SPECIES", 113, 117], ["pigs", "SPECIES", 153, 157], ["pigs", "SPECIES", 198, 202], ["SIV", "SPECIES", 221, 224], ["truncated PA", "PROBLEM", 60, 72], ["higher pathogenicity", "PROBLEM", 255, 275], ["SIV", "OBSERVATION_MODIFIER", 106, 109]]], ["To determine if the high pathogenicity was consistent with enhanced replication in tissues, virus titers in nasal turbinate, trachea, and BALFs were evaluated from three pigs in each group at 3 and 5 dpi.", [["tissues", "ANATOMY", 83, 90], ["nasal turbinate", "ANATOMY", 108, 123], ["trachea", "ANATOMY", 125, 132], ["BALFs", "ANATOMY", 138, 143], ["tissues", "TISSUE", 83, 90], ["nasal turbinate", "MULTI-TISSUE_STRUCTURE", 108, 123], ["trachea", "MULTI-TISSUE_STRUCTURE", 125, 132], ["BALFs", "CANCER", 138, 143], ["pigs", "ORGANISM", 170, 174], ["pigs", "SPECIES", 170, 174], ["pigs", "SPECIES", 170, 174], ["the high pathogenicity", "PROBLEM", 16, 38], ["enhanced replication in tissues", "PROBLEM", 59, 90], ["virus titers in nasal turbinate", "PROBLEM", 92, 123], ["consistent with", "UNCERTAINTY", 43, 58], ["enhanced", "OBSERVATION_MODIFIER", 59, 67], ["replication", "OBSERVATION", 68, 79], ["nasal turbinate", "ANATOMY", 108, 123], ["trachea", "ANATOMY", 125, 132]]], ["For the viral replication in the tissues of inoculated pigs, the replication titers of Sw-41X(WT) in nasal turbinates, tracheas and BALFs were significantly higher than Sw-61X at 3 dpi and/or 5 dpi (P < 0.05) (Fig. 6A\u2013C).", [["tissues", "ANATOMY", 33, 40], ["nasal turbinates", "ANATOMY", 101, 117], ["tracheas", "ANATOMY", 119, 127], ["BALFs", "ANATOMY", 132, 137], ["tissues", "TISSUE", 33, 40], ["pigs", "ORGANISM", 55, 59], ["Sw-41X(WT)", "ORGANISM", 87, 97], ["nasal turbinates", "MULTI-TISSUE_STRUCTURE", 101, 117], ["tracheas", "ORGAN", 119, 127], ["BALFs", "CELL", 132, 137], ["Sw-61X", "GENE_OR_GENE_PRODUCT", 169, 175], ["pigs", "SPECIES", 55, 59], ["pigs", "SPECIES", 55, 59], ["Sw-41X", "SPECIES", 87, 93], ["the viral replication", "PROBLEM", 4, 25], ["inoculated pigs", "TREATMENT", 44, 59], ["Sw", "TEST", 87, 89], ["nasal turbinates", "TREATMENT", 101, 117], ["tracheas and BALFs", "TEST", 119, 137], ["viral replication", "OBSERVATION", 8, 25], ["inoculated pigs", "OBSERVATION", 44, 59], ["nasal turbinates", "ANATOMY", 101, 117], ["tracheas", "ANATOMY", 119, 127]]], ["These results suggested that PA-X with 41 amino acids in X-ORF lead to increased viral replication in vivo.Inhibition of type I interferons expression by truncated or full-length PA-X ::: ResultsWe next explored the potential mechanism behind the enhanced replicatibility and transmissibility virulence of SIV caused by PA-X truncation.", [["amino acids", "CHEMICAL", 42, 53], ["amino acids", "CHEMICAL", 42, 53], ["PA-X", "GENE_OR_GENE_PRODUCT", 29, 33], ["amino acids", "AMINO_ACID", 42, 53], ["X-ORF", "GENE_OR_GENE_PRODUCT", 57, 62], ["type I interferons", "GENE_OR_GENE_PRODUCT", 121, 139], ["SIV", "ORGANISM", 306, 309], ["PA-X", "GENE_OR_GENE_PRODUCT", 320, 324], ["X-ORF", "DNA", 57, 62], ["type I interferons", "PROTEIN", 121, 139], ["SIV", "SPECIES", 306, 309], ["PA", "TEST", 29, 31], ["41 amino acids", "TREATMENT", 39, 53], ["increased viral replication", "TREATMENT", 71, 98], ["type I interferons expression", "TREATMENT", 121, 150], ["the enhanced replicatibility", "PROBLEM", 243, 271], ["transmissibility virulence of SIV", "PROBLEM", 276, 309], ["increased", "OBSERVATION_MODIFIER", 71, 80], ["viral replication", "OBSERVATION", 81, 98]]], ["The induction of type I interferon (IFN-I) establishes an antiviral state which impedes viral replication and spread in host cells12.", [["cells", "ANATOMY", 125, 130], ["type I interferon", "GENE_OR_GENE_PRODUCT", 17, 34], ["IFN-I", "GENE_OR_GENE_PRODUCT", 36, 41], ["host cells", "CELL", 120, 130], ["type I interferon (IFN-I", "PROTEIN", 17, 41], ["host cells", "CELL_TYPE", 120, 130], ["type I interferon (IFN-I)", "TREATMENT", 17, 42], ["an antiviral state", "PROBLEM", 55, 73], ["viral replication", "PROBLEM", 88, 105], ["spread in host cells", "PROBLEM", 110, 130], ["viral replication", "OBSERVATION", 88, 105], ["host cells", "OBSERVATION", 120, 130]]], ["Recently, the PA-X protein of the influenza virus was demonstrated to be involved in the function of host shutoff which could inhibit IFN-I expression9.", [["PA-X", "GENE_OR_GENE_PRODUCT", 14, 18], ["influenza virus", "ORGANISM", 34, 49], ["IFN-I", "GENE_OR_GENE_PRODUCT", 134, 139], ["PA-X protein", "PROTEIN", 14, 26], ["IFN", "PROTEIN", 134, 137], ["influenza virus", "SPECIES", 34, 49], ["influenza virus", "SPECIES", 34, 49], ["the PA", "TEST", 10, 16], ["the influenza virus", "PROBLEM", 30, 49], ["host shutoff", "PROBLEM", 101, 113], ["influenza virus", "OBSERVATION", 34, 49], ["host shutoff", "OBSERVATION", 101, 113]]], ["To assess whether the increased virulence of SIV with truncated PA-X was related to the increased inhibition of IFN-I expression, the expression levels of IFN-\u03b1 and IFN-\u03b2 mRNA in porcine alveolar macrophages (PAMs) and lungs of pigs infected with each virus were analyzed by quantitative real-time PCR as previously described.", [["alveolar macrophages", "ANATOMY", 187, 207], ["PAMs", "ANATOMY", 209, 213], ["lungs", "ANATOMY", 219, 224], ["SIV", "ORGANISM", 45, 48], ["PA-X", "GENE_OR_GENE_PRODUCT", 64, 68], ["IFN-I", "GENE_OR_GENE_PRODUCT", 112, 117], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 155, 160], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 165, 170], ["porcine", "ORGANISM", 179, 186], ["alveolar macrophages", "CELL", 187, 207], ["PAMs", "CELL", 209, 213], ["lungs", "ORGAN", 219, 224], ["pigs", "ORGANISM", 228, 232], ["truncated PA-X", "DNA", 54, 68], ["IFN", "PROTEIN", 112, 115], ["IFN-\u03b1 and IFN-\u03b2 mRNA", "RNA", 155, 175], ["porcine alveolar macrophages", "CELL_TYPE", 179, 207], ["PAMs", "CELL_TYPE", 209, 213], ["porcine", "SPECIES", 179, 186], ["pigs", "SPECIES", 228, 232], ["SIV", "SPECIES", 45, 48], ["pigs", "SPECIES", 228, 232], ["the increased virulence of SIV", "PROBLEM", 18, 48], ["truncated PA", "PROBLEM", 54, 66], ["the increased inhibition of IFN", "PROBLEM", 84, 115], ["the expression levels", "TEST", 130, 151], ["IFN", "TEST", 155, 158], ["IFN", "TEST", 165, 168], ["mRNA in porcine alveolar macrophages", "TREATMENT", 171, 207], ["pigs infected", "PROBLEM", 228, 241], ["each virus", "PROBLEM", 247, 257], ["alveolar macrophages", "OBSERVATION", 187, 207], ["lungs", "ANATOMY", 219, 224]]], ["In PAMs, the expression levels of IFN-\u03b1 and IFN-\u03b2 mRNA from Sw-41X(WT)-infected cells were significantly lower than Sw-61X-infected cells at 12 hpi (P < 0.05) (Fig. 7A).", [["cells", "ANATOMY", 80, 85], ["cells", "ANATOMY", 132, 137], ["PAMs", "CELL", 3, 7], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 34, 39], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 44, 49], ["Sw-41X(WT)", "ORGANISM", 60, 70], ["cells", "CELL", 80, 85], ["Sw-61X", "CELL", 116, 122], ["cells", "CELL", 132, 137], ["PAMs", "CELL_TYPE", 3, 7], ["IFN-\u03b1 and IFN-\u03b2 mRNA", "RNA", 34, 54], ["Sw-41X(WT)-infected cells", "CELL_LINE", 60, 85], ["Sw-61X-infected cells", "CELL_LINE", 116, 137], ["the expression levels", "TEST", 9, 30], ["IFN", "TEST", 34, 37], ["IFN", "TEST", 44, 47], ["mRNA", "TEST", 50, 54], ["Sw", "TEST", 60, 62], ["WT", "TEST", 67, 69], ["infected cells", "PROBLEM", 71, 85], ["Sw", "TEST", 116, 118], ["infected cells", "PROBLEM", 123, 137]]], ["In the lungs of infected pigs, Sw-41X(WT) virus induced a lower level of IFN-I expression than Sw-61X at 3 dpi (P < 0.05) (Fig. 7B).Inhibition of type I interferons expression by truncated or full-length PA-X ::: ResultsTo further confirm the direct effect of PA-X on IFN-I production, we expressed the truncated or full-length PA-X proteins ectopically in 293T cells and then infected them with Sendai virus to stimulate an innate immune response.", [["lungs", "ANATOMY", 7, 12], ["293T cells", "ANATOMY", 357, 367], ["Sw-41X", "CHEMICAL", 31, 37], ["lungs", "ORGAN", 7, 12], ["pigs", "ORGANISM", 25, 29], ["Sw-41X(WT) virus", "ORGANISM", 31, 47], ["IFN-I", "GENE_OR_GENE_PRODUCT", 73, 78], ["Sw-61X", "GENE_OR_GENE_PRODUCT", 95, 101], ["type I interferons", "GENE_OR_GENE_PRODUCT", 146, 164], ["PA-X", "GENE_OR_GENE_PRODUCT", 260, 264], ["IFN-I", "GENE_OR_GENE_PRODUCT", 268, 273], ["PA-X", "GENE_OR_GENE_PRODUCT", 328, 332], ["293T cells", "CELL", 357, 367], ["Sendai virus", "ORGANISM", 396, 408], ["IFN", "PROTEIN", 73, 76], ["type I interferons", "PROTEIN", 146, 164], ["IFN", "PROTEIN", 268, 271], ["truncated or full-length PA-X proteins", "PROTEIN", 303, 341], ["293T cells", "CELL_LINE", 357, 367], ["pigs", "SPECIES", 25, 29], ["pigs", "SPECIES", 25, 29], ["Sw-41X(WT) virus", "SPECIES", 31, 47], ["Sendai virus", "SPECIES", 396, 408], ["infected pigs", "TREATMENT", 16, 29], ["virus", "PROBLEM", 42, 47], ["type I interferons expression", "TREATMENT", 146, 175], ["PA", "TEST", 260, 262], ["Sendai virus", "PROBLEM", 396, 408], ["lungs", "ANATOMY", 7, 12], ["infected", "OBSERVATION", 16, 24]]], ["Activation of IFN-\u03b2 promoter was determined by a luciferase mediated reporter assay13.", [["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 14, 19], ["luciferase", "GENE_OR_GENE_PRODUCT", 49, 59], ["IFN-\u03b2 promoter", "DNA", 14, 28], ["luciferase mediated reporter assay13", "DNA", 49, 85], ["IFN-\u03b2 promoter", "TREATMENT", 14, 28]]], ["We found that IFN-\u03b2 levels in cells expressing full-length PA-X was two-fold higher than cells expressing truncated PA-X (P < 0.05) (Fig. 7C).", [["cells", "ANATOMY", 30, 35], ["cells", "ANATOMY", 89, 94], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 14, 19], ["cells", "CELL", 30, 35], ["PA-X", "GENE_OR_GENE_PRODUCT", 59, 63], ["cells", "CELL", 89, 94], ["PA-X", "GENE_OR_GENE_PRODUCT", 116, 120], ["IFN", "PROTEIN", 14, 17], ["\u03b2", "PROTEIN", 18, 19], ["X", "DNA", 62, 63], ["IFN", "TEST", 14, 17], ["length PA", "TEST", 52, 61], ["truncated PA", "TEST", 106, 118]]], ["In general, these findings indicated that suppressing IFN-I response may contribute to the enhanced virulence of SIV with truncated PA-X.DiscussionAdaptation is thought to be the driving force in evolution, during which beneficial mutations are selected in nature because of increased replication and transmission in the new host.", [["IFN-I", "GENE_OR_GENE_PRODUCT", 54, 59], ["SIV", "ORGANISM", 113, 116], ["PA", "GENE_OR_GENE_PRODUCT", 132, 134], ["IFN", "PROTEIN", 54, 57], ["SIV", "SPECIES", 113, 116], ["the enhanced virulence of SIV", "PROBLEM", 87, 116], ["beneficial mutations", "PROBLEM", 220, 240], ["increased replication", "PROBLEM", 275, 296], ["increased", "OBSERVATION_MODIFIER", 275, 284], ["replication", "OBSERVATION", 285, 296]]], ["Pigs are proposed to be \u201cmixing vessels\u201d or opportune intermediate hosts for the generation of novel influenza viruses with pandemic potential1415.", [["vessels", "ANATOMY", 32, 39], ["influenza viruses", "DISEASE", 101, 118], ["pandemic", "DISEASE", 124, 132], ["Pigs", "ORGANISM", 0, 4], ["vessels", "TISSUE", 32, 39], ["Pigs", "SPECIES", 0, 4], ["Pigs", "TREATMENT", 0, 4], ["novel influenza viruses", "PROBLEM", 95, 118], ["influenza", "OBSERVATION", 101, 110]]], ["Despite the pivotal role of pigs in the ecology of influenza A viruses, few virulence markers of influenza virus in pig are identified.", [["influenza A viruses", "DISEASE", 51, 70], ["influenza virus", "DISEASE", 97, 112], ["pigs", "ORGANISM", 28, 32], ["influenza A viruses", "ORGANISM", 51, 70], ["influenza virus", "ORGANISM", 97, 112], ["pig", "ORGANISM", 116, 119], ["pigs", "SPECIES", 28, 32], ["influenza virus", "SPECIES", 97, 112], ["pig", "SPECIES", 116, 119], ["pigs", "SPECIES", 28, 32], ["influenza A viruses", "SPECIES", 51, 70], ["influenza virus", "SPECIES", 97, 112], ["pig", "SPECIES", 116, 119], ["pigs", "TREATMENT", 28, 32], ["influenza A viruses", "PROBLEM", 51, 70], ["influenza virus", "PROBLEM", 97, 112], ["influenza virus", "OBSERVATION", 97, 112]]], ["Based on the fact that SIVs with truncated PA-X have been gradually increased and became dominan5, we investigate whether truncation of PA-X could adapt SIV for enhanced growth and transmission in pigs.", [["SIVs", "GENE_OR_GENE_PRODUCT", 23, 27], ["PA-X", "GENE_OR_GENE_PRODUCT", 43, 47], ["PA-X", "GENE_OR_GENE_PRODUCT", 136, 140], ["SIV", "ORGANISM", 153, 156], ["pigs", "ORGANISM", 197, 201], ["SIVs", "PROTEIN", 23, 27], ["truncated PA-X", "DNA", 33, 47], ["X", "DNA", 139, 140], ["pigs", "SPECIES", 197, 201], ["SIV", "SPECIES", 153, 156], ["pigs", "SPECIES", 197, 201], ["truncated PA", "TREATMENT", 33, 45], ["dominan5", "PROBLEM", 89, 97], ["truncation of PA", "PROBLEM", 122, 138], ["gradually", "OBSERVATION_MODIFIER", 58, 67], ["increased", "OBSERVATION_MODIFIER", 68, 77]]], ["We observed that truncation of PA-X promoted viral growth in PK15 cells and swine respiratory tissues infected ex vivo, increased the viral replication, pathogenicity and transmission in swine, and we further demonstrated that the altered ability of PA-X in suppressing IFN-I expression might responsible for these changes.", [["PK15 cells", "ANATOMY", 61, 71], ["respiratory tissues", "ANATOMY", 82, 101], ["PA-X", "GENE_OR_GENE_PRODUCT", 31, 35], ["PK15 cells", "CELL", 61, 71], ["swine", "ORGANISM", 76, 81], ["respiratory tissues", "TISSUE", 82, 101], ["swine", "ORGANISM", 187, 192], ["PA-X", "GENE_OR_GENE_PRODUCT", 250, 254], ["IFN-I", "GENE_OR_GENE_PRODUCT", 270, 275], ["X", "DNA", 34, 35], ["PK15 cells", "CELL_LINE", 61, 71], ["IFN", "PROTEIN", 270, 273], ["swine", "SPECIES", 76, 81], ["swine", "SPECIES", 187, 192], ["swine", "SPECIES", 76, 81], ["swine", "SPECIES", 187, 192], ["PA", "TEST", 31, 33], ["viral growth in PK15 cells", "PROBLEM", 45, 71], ["swine respiratory tissues", "PROBLEM", 76, 101], ["the viral replication", "PROBLEM", 130, 151], ["respiratory tissues", "ANATOMY", 82, 101], ["viral replication", "OBSERVATION", 134, 151]]], ["These results suggested that SIV with truncated PA-X seemed to present a selective advantage in pigs, which is in accordance with the fact that the proportion of SIVs possessing truncated PA-X has continually increased and have become predominant in nature.", [["SIV", "ORGANISM", 29, 32], ["PA-X", "GENE_OR_GENE_PRODUCT", 48, 52], ["pigs", "ORGANISM", 96, 100], ["SIVs", "GENE_OR_GENE_PRODUCT", 162, 166], ["PA-X", "GENE_OR_GENE_PRODUCT", 188, 192], ["SIVs", "PROTEIN", 162, 166], ["pigs", "SPECIES", 96, 100], ["SIV", "SPECIES", 29, 32], ["pigs", "SPECIES", 96, 100], ["SIV", "PROBLEM", 29, 32], ["selective", "OBSERVATION_MODIFIER", 73, 82], ["increased", "OBSERVATION_MODIFIER", 209, 218], ["predominant", "OBSERVATION_MODIFIER", 235, 246]]], ["In contrast, our previous study found that the 2009 H1N1, H5N1, and H9N2 influenza viruses with full length PA-X showed higher replication levels in A549 cells than those with truncated PA-X, and that virus with full length PA-X enhanced viral replication and pathogenicity in mice16.", [["A549 cells", "ANATOMY", 149, 159], ["H5N1", "DISEASE", 58, 62], ["influenza", "DISEASE", 73, 82], ["H5N1", "ORGANISM", 58, 62], ["H9N2 influenza viruses", "ORGANISM", 68, 90], ["PA-X", "GENE_OR_GENE_PRODUCT", 108, 112], ["A549 cells", "CELL", 149, 159], ["PA-X", "GENE_OR_GENE_PRODUCT", 186, 190], ["PA-X", "GENE_OR_GENE_PRODUCT", 224, 228], ["full length PA-X", "DNA", 96, 112], ["A549 cells", "CELL_LINE", 149, 159], ["truncated PA-X", "DNA", 176, 190], ["X", "DNA", 227, 228], ["mice16", "DNA", 277, 283], ["H9N2 influenza viruses", "SPECIES", 68, 90], ["H9N2 influenza viruses", "SPECIES", 68, 90], ["our previous study", "TEST", 13, 31], ["H1N1", "PROBLEM", 52, 56], ["H5N1", "PROBLEM", 58, 62], ["H9N2 influenza viruses", "PROBLEM", 68, 90], ["full length PA", "TEST", 96, 110], ["higher replication levels in A549 cells", "PROBLEM", 120, 159], ["truncated PA", "TEST", 176, 188], ["that virus", "PROBLEM", 196, 206], ["full length PA", "TEST", 212, 226], ["enhanced viral replication", "TREATMENT", 229, 255], ["A549 cells", "OBSERVATION", 149, 159], ["viral replication", "OBSERVATION", 238, 255]]], ["Coincidently, all of the avian and human influenza viruses possessed full-length PA-X in nature.", [["avian", "ORGANISM", 25, 30], ["human", "ORGANISM", 35, 40], ["influenza viruses", "ORGANISM", 41, 58], ["PA-X", "GENE_OR_GENE_PRODUCT", 81, 85], ["full-length PA-X", "DNA", 69, 85], ["avian", "SPECIES", 25, 30], ["human", "SPECIES", 35, 40], ["human influenza viruses", "SPECIES", 35, 58], ["human influenza viruses", "PROBLEM", 35, 58]]], ["Therefore, we speculate that the role of length of PA-X is associated with host specificity.DiscussionIFN-I consist of several structurally related IFN-\u03b1 proteins and a single IFN-\u03b2 protein, together with interferon-stimulated genes (ISGs), they establish an antiviral state in infected cells that function to inhibit viral replication and restrict viral spread17.", [["cells", "ANATOMY", 287, 292], ["PA-X", "GENE_OR_GENE_PRODUCT", 51, 55], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 148, 153], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 176, 181], ["interferon-stimulated genes", "GENE_OR_GENE_PRODUCT", 205, 232], ["cells", "CELL", 287, 292], ["spread17", "GENE_OR_GENE_PRODUCT", 355, 363], ["IFN", "PROTEIN", 148, 151], ["\u03b1 proteins", "PROTEIN", 152, 162], ["IFN-\u03b2 protein", "PROTEIN", 176, 189], ["interferon-stimulated genes", "DNA", 205, 232], ["ISGs", "DNA", 234, 238], ["infected cells", "CELL_TYPE", 278, 292], ["viral spread17", "DNA", 349, 363], ["a single IFN-\u03b2 protein", "TEST", 167, 189], ["interferon", "TREATMENT", 205, 215], ["an antiviral state", "PROBLEM", 256, 274], ["infected cells", "PROBLEM", 278, 292], ["viral replication", "TREATMENT", 318, 335]]], ["To escape the antiviral response of the host, several viral proteins have been shown to suppress IFN-I expression, including vhs from herpes simplex virus (HSV) and nsp1 from severe acute respiratory syndrome-related coronavirus (SARS-CoV) or mouse hepatitis virus (MHV), that is necessary for efficient virus growth and virulence181920212223242526.", [["herpes simplex virus", "DISEASE", 134, 154], ["acute respiratory syndrome-related coronavirus (SARS-CoV) or mouse hepatitis virus", "DISEASE", 182, 264], ["IFN-I", "GENE_OR_GENE_PRODUCT", 97, 102], ["vhs", "GENE_OR_GENE_PRODUCT", 125, 128], ["herpes simplex virus", "ORGANISM", 134, 154], ["HSV", "ORGANISM", 156, 159], ["nsp1", "GENE_OR_GENE_PRODUCT", 165, 169], ["severe acute respiratory syndrome-related coronavirus", "ORGANISM", 175, 228], ["SARS-CoV", "ORGANISM", 230, 238], ["mouse hepatitis virus", "ORGANISM", 243, 264], ["MHV", "ORGANISM", 266, 269], ["viral proteins", "PROTEIN", 54, 68], ["IFN", "PROTEIN", 97, 100], ["herpes simplex virus", "SPECIES", 134, 154], ["mouse", "SPECIES", 243, 248], ["hepatitis virus", "SPECIES", 249, 264], ["herpes simplex virus", "SPECIES", 134, 154], ["HSV", "SPECIES", 156, 159], ["severe acute respiratory syndrome-related coronavirus", "SPECIES", 175, 228], ["SARS-CoV", "SPECIES", 230, 238], ["mouse hepatitis virus", "SPECIES", 243, 264], ["MHV", "SPECIES", 266, 269], ["several viral proteins", "PROBLEM", 46, 68], ["vhs", "PROBLEM", 125, 128], ["herpes simplex virus", "PROBLEM", 134, 154], ["HSV", "PROBLEM", 156, 159], ["nsp1", "PROBLEM", 165, 169], ["severe acute respiratory syndrome", "PROBLEM", 175, 208], ["coronavirus (SARS-CoV)", "PROBLEM", 217, 239], ["mouse hepatitis virus", "PROBLEM", 243, 264], ["efficient virus growth", "PROBLEM", 294, 316], ["virulence", "PROBLEM", 321, 330], ["antiviral response", "OBSERVATION", 14, 32], ["herpes simplex virus", "OBSERVATION", 134, 154], ["severe", "OBSERVATION_MODIFIER", 175, 181], ["acute", "OBSERVATION_MODIFIER", 182, 187], ["respiratory syndrome", "OBSERVATION", 188, 208]]], ["For the influenza virus, the newly identified PA-X protein, along with NS1, PB2, PB1, PA and PB1-F2 have been demonstrated to be involved in the IFN-I response modulation27.", [["influenza virus", "ORGANISM", 8, 23], ["PA-X", "GENE_OR_GENE_PRODUCT", 46, 50], ["NS1", "GENE_OR_GENE_PRODUCT", 71, 74], ["PB2", "GENE_OR_GENE_PRODUCT", 76, 79], ["PB1", "GENE_OR_GENE_PRODUCT", 81, 84], ["PA", "GENE_OR_GENE_PRODUCT", 86, 88], ["PB1-F2", "GENE_OR_GENE_PRODUCT", 93, 99], ["IFN-I", "GENE_OR_GENE_PRODUCT", 145, 150], ["X protein", "PROTEIN", 49, 58], ["NS1", "PROTEIN", 71, 74], ["PB2", "PROTEIN", 76, 79], ["PB1", "PROTEIN", 81, 84], ["PA", "PROTEIN", 86, 88], ["PB1", "PROTEIN", 93, 96], ["F2", "PROTEIN", 97, 99], ["IFN", "PROTEIN", 145, 148], ["influenza virus", "SPECIES", 8, 23], ["influenza virus", "SPECIES", 8, 23], ["the influenza virus", "PROBLEM", 4, 23], ["PA-X protein", "TEST", 46, 58], ["NS1", "TEST", 71, 74], ["PB2", "TEST", 76, 79], ["PB1", "TEST", 81, 84], ["PA", "TEST", 86, 88], ["PB1", "TEST", 93, 96]]], ["The most prominent IFN-I antagonist in influenza virus is the NS1 protein which can suppress the IFN-I response by interacting with RIG-I and TRIM25282930.", [["influenza", "DISEASE", 39, 48], ["IFN-I", "GENE_OR_GENE_PRODUCT", 19, 24], ["influenza virus", "ORGANISM", 39, 54], ["NS1", "GENE_OR_GENE_PRODUCT", 62, 65], ["IFN-I", "GENE_OR_GENE_PRODUCT", 97, 102], ["RIG-I", "GENE_OR_GENE_PRODUCT", 132, 137], ["IFN", "PROTEIN", 19, 22], ["NS1 protein", "PROTEIN", 62, 73], ["IFN", "PROTEIN", 97, 100], ["RIG-I", "PROTEIN", 132, 137], ["influenza virus", "SPECIES", 39, 54], ["influenza virus", "SPECIES", 39, 54], ["The most prominent IFN-I antagonist", "TREATMENT", 0, 35], ["influenza virus", "PROBLEM", 39, 54], ["the NS1 protein", "TREATMENT", 58, 73], ["most prominent", "OBSERVATION_MODIFIER", 4, 18], ["influenza virus", "OBSERVATION", 39, 54]]], ["Graef et al. demonstrated that the PB2 subunit of the influenza virus RNA polymerase complex interacted with MAVS and inhibited MAVS-mediated IFN-\u03b2 expression31.", [["influenza virus", "ORGANISM", 54, 69], ["MAVS", "GENE_OR_GENE_PRODUCT", 109, 113], ["MAVS", "GENE_OR_GENE_PRODUCT", 128, 132], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 142, 147], ["PB2 subunit", "PROTEIN", 35, 46], ["influenza virus RNA polymerase complex", "PROTEIN", 54, 92], ["MAVS", "PROTEIN", 109, 113], ["MAVS", "PROTEIN", 128, 132], ["IFN", "PROTEIN", 142, 145], ["\u03b2", "PROTEIN", 146, 147], ["influenza virus", "SPECIES", 54, 69], ["influenza virus", "SPECIES", 54, 69], ["the PB2 subunit", "TREATMENT", 31, 46], ["the influenza virus RNA polymerase complex", "PROBLEM", 50, 92], ["MAVS", "PROBLEM", 109, 113], ["MAVS", "TEST", 128, 132]]], ["Additionally, the other polymerase proteins PB1 and PA were identified as part of the IFN-I inhibitory strategy evolved by influenza virus and suggested to interact with RIG-I, subsequently inhibiting RIG-I mediated IFN-I signaling32.", [["PB1", "GENE_OR_GENE_PRODUCT", 44, 47], ["PA", "GENE_OR_GENE_PRODUCT", 52, 54], ["IFN-I", "GENE_OR_GENE_PRODUCT", 86, 91], ["influenza virus", "ORGANISM", 123, 138], ["RIG-I", "GENE_OR_GENE_PRODUCT", 170, 175], ["RIG-I", "GENE_OR_GENE_PRODUCT", 201, 206], ["IFN-I", "GENE_OR_GENE_PRODUCT", 216, 221], ["polymerase proteins", "PROTEIN", 24, 43], ["PB1", "PROTEIN", 44, 47], ["PA", "PROTEIN", 52, 54], ["IFN", "PROTEIN", 86, 89], ["RIG-I", "PROTEIN", 170, 175], ["RIG-I mediated IFN-I signaling32", "PROTEIN", 201, 233], ["influenza virus", "SPECIES", 123, 138], ["influenza virus", "SPECIES", 123, 138], ["the other polymerase proteins PB1", "TEST", 14, 47], ["PA", "TEST", 52, 54], ["the IFN-I inhibitory strategy", "TREATMENT", 82, 111], ["influenza virus", "PROBLEM", 123, 138], ["RIG", "TEST", 201, 204], ["influenza virus", "OBSERVATION", 123, 138]]], ["Effects outlined of the PB1-F2 are strain specific, however interferon suppression seems to be a common property, as A/Hong Kong/156/1997 (H5N1) as well as PR8 (H1N1) strains both exhibit IFN-\u03b2 antagonism27.", [["PB1-F2", "GENE_OR_GENE_PRODUCT", 24, 30], ["A/Hong Kong/156/1997 (H5N1)", "ORGANISM", 117, 144], ["PR8 (H1N1)", "ORGANISM", 156, 166], ["strains", "ORGANISM", 167, 174], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 188, 193], ["PB1", "DNA", 24, 27], ["interferon", "PROTEIN", 60, 70], ["IFN", "PROTEIN", 188, 191], ["\u03b2 antagonism27", "PROTEIN", 192, 206], ["Hong Kong/156/1997 (H5N1", "SPECIES", 119, 143], ["the PB1", "TEST", 20, 27], ["strain", "PROBLEM", 35, 41], ["interferon suppression", "PROBLEM", 60, 82], ["H5N1", "PROBLEM", 139, 143], ["strains", "PROBLEM", 167, 174], ["IFN", "TEST", 188, 191]]], ["More recently, Hayashi et al. reported that the presence of PA-X in A/California/04/2009 (H1N1) also resulted in a suppression of IFN-\u03b2 mRNA production through the shutoff activity of PA-X, leading to more efficient viral replication and more severe lung pathology in infected cells and mice9.", [["lung", "ANATOMY", 250, 254], ["cells", "ANATOMY", 277, 282], ["PA-X", "GENE_OR_GENE_PRODUCT", 60, 64], ["A/California/04/2009", "ORGANISM", 68, 88], ["H1N1", "ORGANISM", 90, 94], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 130, 135], ["PA-X", "GENE_OR_GENE_PRODUCT", 184, 188], ["lung", "ORGAN", 250, 254], ["cells", "CELL", 277, 282], ["mice9", "CELL", 287, 292], ["IFN-\u03b2 mRNA", "RNA", 130, 140], ["infected cells", "CELL_TYPE", 268, 282], ["A/California/04/2009 (H1N1", "SPECIES", 68, 94], ["H1N1", "PROBLEM", 90, 94], ["IFN", "PROBLEM", 130, 133], ["mRNA production", "PROBLEM", 136, 151], ["efficient viral replication", "PROBLEM", 206, 233], ["more severe lung pathology in infected cells", "PROBLEM", 238, 282], ["viral replication", "OBSERVATION", 216, 233], ["severe", "OBSERVATION_MODIFIER", 243, 249], ["lung", "ANATOMY", 250, 254], ["pathology", "OBSERVATION", 255, 264], ["infected cells", "OBSERVATION", 268, 282]]], ["Here, we clearly showed that truncated PA-X was more effective in inhibiting IFN-I mRNA expression in PAMs and pigs through the shutoff activity of PA-X, which is consisted with the enhanced replication, pathogenicity and transmissibility of PA-X mutants in pigs.", [["PA-X", "GENE_OR_GENE_PRODUCT", 39, 43], ["IFN-I", "GENE_OR_GENE_PRODUCT", 77, 82], ["PAMs", "CELL", 102, 106], ["pigs", "ORGANISM", 111, 115], ["PA-X", "GENE_OR_GENE_PRODUCT", 148, 152], ["PA-X", "GENE_OR_GENE_PRODUCT", 242, 246], ["pigs", "ORGANISM", 258, 262], ["IFN-I mRNA", "RNA", 77, 87], ["PAMs", "CELL_TYPE", 102, 106], ["pigs", "SPECIES", 111, 115], ["pigs", "SPECIES", 258, 262], ["pigs", "SPECIES", 111, 115], ["pigs", "SPECIES", 258, 262], ["truncated PA", "PROBLEM", 29, 41], ["pigs", "TREATMENT", 111, 115], ["the enhanced replication", "PROBLEM", 178, 202], ["pathogenicity", "PROBLEM", 204, 217], ["PA", "TEST", 242, 244], ["enhanced", "OBSERVATION_MODIFIER", 182, 190], ["replication", "OBSERVATION", 191, 202]]], ["Therefore, our study provides evidence that the adaptation of SIV in pigs may be partly due to the shutoff activity of PA-X.DiscussionIn summary, we found that truncation of PA-X played an important role in the adaptation of SIV in pigs.", [["SIV", "ORGANISM", 62, 65], ["pigs", "ORGANISM", 69, 73], ["PA-X", "GENE_OR_GENE_PRODUCT", 174, 178], ["SIV", "ORGANISM", 225, 228], ["pigs", "ORGANISM", 232, 236], ["PA-X", "DNA", 174, 178], ["pigs", "SPECIES", 69, 73], ["pigs", "SPECIES", 232, 236], ["SIV", "SPECIES", 62, 65], ["pigs", "SPECIES", 69, 73], ["SIV", "SPECIES", 225, 228], ["pigs", "SPECIES", 232, 236], ["our study", "TEST", 11, 20], ["SIV in pigs", "TREATMENT", 62, 73], ["truncation of PA", "PROBLEM", 160, 176]]], ["Compared with that of full length PA-X, it conferred increased viral pathogenicity, replication and transmissibility in pigs, promoted viral growth in PK15 cells and swine respiratory tissues infected ex vivo, and greater inhibition of host IFN-I expression, which was consistent with the increasing occurrence of SIV with truncated PA-X.Ethics statement ::: Materials and MethodsAll animal work was approved by the Beijing Association for Science and Technology (approval ID SYXK [Beijing] 2007\u20130023) and conducted in strict accordance with the Beijing Laboratory Animal Welfare and Ethics guidelines, as issued by the Beijing Administration Committee of Laboratory Animals, and in accordance with the China Agricultural University (CAU) Institutional Animal Care and Use Committee guidelines (ID: SKLAB-B-2010\u2013003).", [["PK15 cells", "ANATOMY", 151, 161], ["respiratory tissues", "ANATOMY", 172, 191], ["PA-X", "GENE_OR_GENE_PRODUCT", 34, 38], ["pigs", "ORGANISM", 120, 124], ["PK15 cells", "CELL", 151, 161], ["swine", "ORGANISM", 166, 171], ["respiratory tissues", "TISSUE", 172, 191], ["IFN-I", "GENE_OR_GENE_PRODUCT", 241, 246], ["SIV", "ORGANISM", 314, 317], ["PK15 cells", "CELL_LINE", 151, 161], ["IFN", "PROTEIN", 241, 244], ["pigs", "SPECIES", 120, 124], ["swine", "SPECIES", 166, 171], ["pigs", "SPECIES", 120, 124], ["swine", "SPECIES", 166, 171], ["SIV", "SPECIES", 314, 317], ["increased viral pathogenicity", "PROBLEM", 53, 82], ["pigs", "TREATMENT", 120, 124], ["viral growth in PK15 cells", "PROBLEM", 135, 161], ["swine respiratory tissues", "PROBLEM", 166, 191], ["increased", "OBSERVATION_MODIFIER", 53, 62], ["viral pathogenicity", "OBSERVATION", 63, 82], ["viral", "OBSERVATION_MODIFIER", 135, 140], ["growth", "OBSERVATION_MODIFIER", 141, 147], ["respiratory tissues", "ANATOMY", 172, 191], ["consistent with", "UNCERTAINTY", 269, 284]]], ["The animal use protocol was approved by the Animal Welfare Committee of the CAU.Viruses and cells ::: Materials and MethodsA/swine/Guangdong/1222/2006 [Sw-41X(WT)] is a TR H1N2 swine influenza virus which has been previously described10.", [["cells", "ANATOMY", 92, 97], ["influenza virus", "DISEASE", 183, 198], ["Viruses", "CELL", 80, 87], ["cells", "CELL", 92, 97], ["MethodsA/swine", "ORGANISM", 116, 130], ["Guangdong/1222/2006", "ORGANISM", 131, 150], ["Sw-41X(WT)", "ORGANISM", 152, 162], ["TR H1N2 swine influenza virus", "ORGANISM", 169, 198], ["swine", "SPECIES", 125, 130], ["H1N2 swine influenza virus", "SPECIES", 172, 198], ["Guangdong/1222/2006 [Sw-41X", "SPECIES", 131, 158], ["TR H1N2 swine influenza virus", "SPECIES", 169, 198], ["a TR H1N2 swine influenza virus", "PROBLEM", 167, 198]]], ["The Human embryonic kidney cell (293T), Madin Darby canine kidney cell (MDCK), porcine kidney cell (PK15), and porcine alveolar macrophages (PAMs) were kept in our laboratory.", [["embryonic kidney cell", "ANATOMY", 10, 31], ["293T", "ANATOMY", 33, 37], ["Madin Darby canine kidney cell", "ANATOMY", 40, 70], ["MDCK", "ANATOMY", 72, 76], ["kidney cell", "ANATOMY", 87, 98], ["PK15", "ANATOMY", 100, 104], ["alveolar macrophages", "ANATOMY", 119, 139], ["PAMs", "ANATOMY", 141, 145], ["Human", "ORGANISM", 4, 9], ["embryonic kidney cell", "CELL", 10, 31], ["293T", "CELL", 33, 37], ["Madin Darby canine kidney cell", "CELL", 40, 70], ["MDCK", "CELL", 72, 76], ["porcine kidney cell", "CELL", 79, 98], ["PK15", "CELL", 100, 104], ["porcine", "ORGANISM", 111, 118], ["alveolar macrophages", "CELL", 119, 139], ["PAMs", "CELL", 141, 145], ["Human embryonic kidney cell", "CELL_LINE", 4, 31], ["293T", "CELL_LINE", 33, 37], ["Madin Darby canine kidney cell", "CELL_LINE", 40, 70], ["MDCK", "CELL_LINE", 72, 76], ["porcine kidney cell", "CELL_LINE", 79, 98], ["PK15", "CELL_LINE", 100, 104], ["porcine alveolar macrophages", "CELL_TYPE", 111, 139], ["PAMs", "CELL_TYPE", 141, 145], ["Human", "SPECIES", 4, 9], ["porcine", "SPECIES", 79, 86], ["porcine", "SPECIES", 111, 118], ["The Human embryonic kidney cell", "TEST", 0, 31], ["Madin Darby canine kidney cell", "TEST", 40, 70], ["MDCK", "TEST", 72, 76], ["porcine kidney cell", "TEST", 79, 98], ["PK15", "TEST", 100, 104], ["porcine alveolar macrophages", "PROBLEM", 111, 139], ["embryonic kidney cell", "OBSERVATION", 10, 31], ["kidney", "ANATOMY", 59, 65], ["cell", "OBSERVATION", 66, 70], ["kidney", "ANATOMY", 87, 93], ["cell", "OBSERVATION", 94, 98], ["alveolar macrophages", "OBSERVATION", 119, 139]]], ["The 293T, MDCK, and PK15 cells were maintained in Dulbecco\u2019s modified Eagle\u2019s medium (DMEM, Gibco).", [["293T", "ANATOMY", 4, 8], ["MDCK", "ANATOMY", 10, 14], ["PK15 cells", "ANATOMY", 20, 30], ["293T", "CELL", 4, 8], ["MDCK", "CELL", 10, 14], ["PK15 cells", "CELL", 20, 30], ["293T", "CELL_LINE", 4, 8], ["MDCK", "CELL_LINE", 10, 14], ["PK15 cells", "CELL_LINE", 20, 30], ["MDCK", "TEST", 10, 14], ["PK15 cells", "TEST", 20, 30]]], ["The PAMs were maintained in RPMI 1640 medium (Gibco).", [["PAMs", "CELL", 4, 8], ["PAMs", "CELL_TYPE", 4, 8]]], ["The DMEM and RPMI 1640 media were supplemented with 10% fetal bovine serum (FBS, Gibco), 100 units/ml of penicillin, and 100 \u03bcg/ml of streptomycin; and all of the cells cultured at 37 \u00b0C in a 5% CO2 atmosphere.Generation of recombinant viruses by reverse genetics ::: Materials and MethodsAll eight gene segments were amplified by reverse transcription (RT)-PCR from Sw-41X(WT) virus, and cloned into the dual-promoter plasmid pHW2000.", [["fetal bovine serum", "ANATOMY", 56, 74], ["FBS", "ANATOMY", 76, 79], ["cells", "ANATOMY", 163, 168], ["penicillin", "CHEMICAL", 105, 115], ["streptomycin", "CHEMICAL", 134, 146], ["CO2", "CHEMICAL", 195, 198], ["penicillin", "CHEMICAL", 105, 115], ["streptomycin", "CHEMICAL", 134, 146], ["CO2", "CHEMICAL", 195, 198], ["bovine", "ORGANISM", 62, 68], ["serum", "ORGANISM_SUBSTANCE", 69, 74], ["FBS", "ORGANISM_SUBSTANCE", 76, 79], ["Gibco", "ORGANISM_SUBSTANCE", 81, 86], ["penicillin", "SIMPLE_CHEMICAL", 105, 115], ["streptomycin", "SIMPLE_CHEMICAL", 134, 146], ["cells", "CELL", 163, 168], ["CO2", "SIMPLE_CHEMICAL", 195, 198], ["Sw-41X(WT) virus", "ORGANISM", 367, 383], ["reverse transcription (RT)-PCR", "DNA", 331, 361], ["dual-promoter plasmid", "DNA", 405, 426], ["pHW2000", "DNA", 427, 434], ["bovine", "SPECIES", 62, 68], ["bovine", "SPECIES", 62, 68], ["Sw-41X(WT) virus", "SPECIES", 367, 383], ["10% fetal bovine serum (FBS", "TREATMENT", 52, 79], ["Gibco", "TEST", 81, 86], ["penicillin", "TREATMENT", 105, 115], ["streptomycin", "TREATMENT", 134, 146], ["the cells", "TEST", 159, 168], ["a 5% CO2 atmosphere", "TREATMENT", 190, 209], ["Materials", "TREATMENT", 268, 277], ["Methods", "TREATMENT", 282, 289], ["PCR", "TEST", 358, 361], ["the dual-promoter plasmid pHW2000", "TREATMENT", 401, 434], ["recombinant viruses", "OBSERVATION", 224, 243]]], ["The mutations were introduced into the PA gene using a Site-directed QuikChange Mutagenesis kit (Agilent) according to the manufacturer\u2019s instructions.", [["PA", "GENE_OR_GENE_PRODUCT", 39, 41], ["PA gene", "DNA", 39, 46], ["The mutations", "TREATMENT", 0, 13], ["the PA gene", "TREATMENT", 35, 46], ["a Site-directed QuikChange Mutagenesis kit (Agilent)", "TREATMENT", 53, 105]]], ["PCR primer sequences are available upon request.", [["PCR primer sequences", "DNA", 0, 20], ["PCR primer sequences", "TEST", 0, 20]]], ["The TR H1N2 SIV with full-length PA-X (61aa), Sw-61X, was constructed by extending PA-X from 41aa to 61aa on the backbone of Sw-41X(WT) virus.", [["TR H1N2 SIV", "ORGANISM", 4, 15], ["PA-X", "GENE_OR_GENE_PRODUCT", 33, 37], ["Sw-61X", "GENE_OR_GENE_PRODUCT", 46, 52], ["PA-X", "GENE_OR_GENE_PRODUCT", 83, 87], ["Sw-41X(WT) virus", "ORGANISM", 125, 141], ["X", "DNA", 36, 37], ["Sw-61X", "DNA", 46, 52], ["PA-X", "DNA", 83, 87], ["H1N2 SIV", "SPECIES", 7, 15], ["TR H1N2 SIV", "SPECIES", 4, 15], ["Sw-41X", "SPECIES", 125, 131], ["The TR H1N2 SIV", "PROBLEM", 0, 15], ["length PA", "TEST", 26, 35], ["Sw", "TEST", 46, 48], ["extending PA", "TEST", 73, 85], ["aa", "TEST", 95, 97], ["Sw", "TEST", 125, 127], ["virus", "PROBLEM", 136, 141], ["H1N2 SIV", "OBSERVATION", 7, 15]]], ["Substitution from stop codon (UAG) to tryptophan (UGG) codon at position 42 in the X-ORF did not change the PA ORF (Fig. 2).", [["tryptophan", "CHEMICAL", 38, 48], ["tryptophan", "CHEMICAL", 38, 48], ["tryptophan", "AMINO_ACID", 38, 48], ["tryptophan (UGG) codon", "DNA", 38, 60], ["position 42", "DNA", 64, 75], ["X-ORF", "DNA", 83, 88], ["PA ORF", "DNA", 108, 114], ["Substitution", "TREATMENT", 0, 12], ["codon (UAG", "TREATMENT", 23, 33], ["tryptophan (UGG) codon", "TREATMENT", 38, 60]]], ["Rescued viruses were detected using haemagglutination assays.", [["Rescued viruses", "PROBLEM", 0, 15], ["haemagglutination assays", "TEST", 36, 60], ["viruses", "OBSERVATION", 8, 15]]], ["Viral RNA was extracted and analysed by RT-PCR, and each viral segment was sequenced to confirm sequence identity.Viral titration and growth kinetics ::: Materials and MethodsThe 50% tissue culture infectious dose (TCID50) was determined in MDCK cells with 10-fold serially diluted viruses inoculated at 37 \u00b0C for 72 h, as previous studies with Reed-Muench method3334.", [["tissue", "ANATOMY", 183, 189], ["MDCK cells", "ANATOMY", 241, 251], ["tissue", "TISSUE", 183, 189], ["MDCK cells", "CELL", 241, 251], ["Viral RNA", "RNA", 0, 9], ["viral segment", "DNA", 57, 70], ["MDCK cells", "CELL_LINE", 241, 251], ["Viral RNA", "PROBLEM", 0, 9], ["PCR", "TEST", 43, 46], ["Viral titration", "TEST", 114, 129], ["Methods", "TREATMENT", 168, 175], ["MDCK cells", "TEST", 241, 251], ["previous studies", "TEST", 323, 339]]], ["Multistep replication kinetics was determined by inoculating PK15 cells with a MOI of 0.01.", [["PK15 cells", "ANATOMY", 61, 71], ["PK15 cells", "CELL", 61, 71], ["PK15 cells", "CELL_LINE", 61, 71], ["Multistep replication kinetics", "PROBLEM", 0, 30], ["a MOI", "TEST", 77, 82], ["replication kinetics", "OBSERVATION", 10, 30]]], ["Supernatants were sampled at 6, 12, 24, 36, 48, 60, and 72 hours post-inoculation (hpi) and titrated by inoculating MDCK cells in 96-well plates.", [["Supernatants", "ANATOMY", 0, 12], ["MDCK cells", "ANATOMY", 116, 126], ["Supernatants", "CELL", 0, 12], ["MDCK cells", "CELL", 116, 126], ["MDCK cells", "CELL_LINE", 116, 126], ["Supernatants", "TEST", 0, 12], ["inoculating MDCK cells", "TEST", 104, 126]]], ["Three independent experiments were performed.Isolation, culture, and infection of porcine respiratory explants ::: Materials and MethodsPorcine nasal turbinate, trachea, and lung explants were prepared as described previously113536.", [["nasal turbinate", "ANATOMY", 144, 159], ["trachea", "ANATOMY", 161, 168], ["lung explants", "ANATOMY", 174, 187], ["infection", "DISEASE", 69, 78], ["porcine", "ORGANISM", 82, 89], ["nasal turbinate", "MULTI-TISSUE_STRUCTURE", 144, 159], ["trachea", "MULTI-TISSUE_STRUCTURE", 161, 168], ["lung explants", "MULTI-TISSUE_STRUCTURE", 174, 187], ["porcine", "SPECIES", 82, 89], ["porcine", "SPECIES", 82, 89], ["Isolation, culture", "TEST", 45, 63], ["Materials", "TREATMENT", 115, 124], ["MethodsPorcine nasal turbinate", "TREATMENT", 129, 159], ["nasal turbinate", "ANATOMY", 144, 159], ["trachea", "ANATOMY", 161, 168], ["lung", "ANATOMY", 174, 178], ["explants", "OBSERVATION", 179, 187]]], ["All respiratory explants were cultured at an air-liquid interface in 12-well plates at 37 \u00b0C in 5% CO2 atmosphere.", [["respiratory explants", "ANATOMY", 4, 24], ["CO2", "CHEMICAL", 99, 102], ["CO2", "CHEMICAL", 99, 102], ["CO2", "SIMPLE_CHEMICAL", 99, 102], ["All respiratory explants", "PROBLEM", 0, 24], ["an air-liquid interface", "TEST", 42, 65], ["respiratory explants", "OBSERVATION", 4, 24]]], ["At 24 h of culture, explants were washed with PBS, and 106 TCID50 of each virus diluted in 500 \u03bcl explant medium were deposited in the upper compartment of Transwells for 1 h at 37 \u00b0C. Subsequently, explants were washed three times with PBS and the culture was replenished with 500 \u03bcl of explant media.", [["explants", "ANATOMY", 20, 28], ["upper compartment", "ANATOMY", 135, 152], ["explants", "ANATOMY", 199, 207], ["explants", "CELL", 20, 28], ["culture", "TEST", 11, 18], ["PBS", "TREATMENT", 46, 49], ["each virus", "TREATMENT", 69, 79], ["PBS", "TREATMENT", 237, 240], ["the culture", "TEST", 245, 256], ["explant media", "TREATMENT", 288, 301], ["upper", "ANATOMY_MODIFIER", 135, 140]]], ["At 24, 48, and 72 hpi, 100 \u03bcl supernatant was collected to assess virus yields.Infection and transmission of SIV in pigs ::: Materials and MethodsFour-week-old, landrace piglets that were free of influenza virus, porcine reproductive and respiratory syndrome virus (PRRSV), classic swine fever virus (CSFV), pseudorabies virus (PRV), porcine circovirus type 2 (PCV2) and M. hyopneumoniae infections were obtained from Beijing Center of SPF Swine Breeding & Management.", [["supernatant", "ANATOMY", 30, 41], ["influenza virus", "DISEASE", 196, 211], ["porcine reproductive and respiratory syndrome", "DISEASE", 213, 258], ["swine fever", "DISEASE", 282, 293], ["pseudorabies virus", "DISEASE", 308, 326], ["porcine circovirus type", "DISEASE", 334, 357], ["M. hyopneumoniae infections", "DISEASE", 371, 398], ["SIV", "ORGANISM", 109, 112], ["pigs", "ORGANISM", 116, 120], ["piglets", "ORGANISM", 170, 177], ["influenza virus", "ORGANISM", 196, 211], ["porcine reproductive and respiratory syndrome virus", "ORGANISM", 213, 264], ["PRRSV", "ORGANISM", 266, 271], ["classic swine fever virus", "ORGANISM", 274, 299], ["CSFV", "ORGANISM", 301, 305], ["pseudorabies virus", "ORGANISM", 308, 326], ["porcine circovirus type 2", "ORGANISM", 334, 359], ["PCV2", "ORGANISM", 361, 365], ["M. hyopneumoniae", "ORGANISM", 371, 387], ["pigs", "SPECIES", 116, 120], ["piglets", "SPECIES", 170, 177], ["influenza virus", "SPECIES", 196, 211], ["porcine reproductive and respiratory syndrome virus", "SPECIES", 213, 264], ["PRRSV", "SPECIES", 266, 271], ["swine fever virus", "SPECIES", 282, 299], ["CSFV", "SPECIES", 301, 305], ["pseudorabies virus", "SPECIES", 308, 326], ["porcine circovirus", "SPECIES", 334, 352], ["M. hyopneumoniae", "SPECIES", 371, 387], ["SIV", "SPECIES", 109, 112], ["pigs", "SPECIES", 116, 120], ["influenza virus", "SPECIES", 196, 211], ["porcine reproductive and respiratory syndrome virus", "SPECIES", 213, 264], ["PRRSV", "SPECIES", 266, 271], ["swine fever virus", "SPECIES", 282, 299], ["CSFV", "SPECIES", 301, 305], ["pseudorabies virus", "SPECIES", 308, 326], ["PRV", "SPECIES", 328, 331], ["porcine circovirus type 2", "SPECIES", 334, 359], ["PCV2", "SPECIES", 361, 365], ["M. hyopneumoniae", "SPECIES", 371, 387], ["Infection", "PROBLEM", 79, 88], ["Methods", "TEST", 139, 146], ["landrace piglets", "TREATMENT", 161, 177], ["influenza virus", "PROBLEM", 196, 211], ["porcine reproductive", "PROBLEM", 213, 233], ["respiratory syndrome virus", "PROBLEM", 238, 264], ["classic swine fever virus", "PROBLEM", 274, 299], ["CSFV", "PROBLEM", 301, 305], ["pseudorabies virus", "PROBLEM", 308, 326], ["porcine circovirus type 2", "PROBLEM", 334, 359], ["PCV2", "PROBLEM", 361, 365], ["M. hyopneumoniae infections", "PROBLEM", 371, 398], ["influenza virus", "OBSERVATION", 196, 211], ["respiratory syndrome", "OBSERVATION", 238, 258], ["hyopneumoniae infections", "OBSERVATION", 374, 398]]], ["Nine pigs from each group were inoculated intranasally with 106 TCID50 of tested virus, delivered in a final volume of 2 ml per nostril, using a mucosal atomization device (MAD, Wolfe Tory Medical, Inc.) to mimic aerogenic infection.", [["intranasally", "ANATOMY", 42, 54], ["nostril", "ANATOMY", 128, 135], ["mucosal", "ANATOMY", 145, 152], ["aerogenic infection", "DISEASE", 213, 232], ["pigs", "ORGANISM", 5, 9], ["nostril", "ORGAN", 128, 135], ["pigs", "SPECIES", 5, 9], ["pigs", "SPECIES", 5, 9], ["tested virus", "PROBLEM", 74, 86], ["a mucosal atomization device", "TREATMENT", 143, 171], ["aerogenic infection", "PROBLEM", 213, 232], ["infection", "OBSERVATION", 223, 232]]], ["Five uninfected pigs were maintained as a control group and were mock-inoculated with 2 ml PBS per nostril, using the same method as the infected pigs.", [["nostril", "ANATOMY", 99, 106], ["pigs", "ORGANISM", 16, 20], ["nostril", "ORGANISM_SUBDIVISION", 99, 106], ["pigs", "ORGANISM", 146, 150], ["pigs", "SPECIES", 16, 20], ["pigs", "SPECIES", 146, 150], ["pigs", "SPECIES", 16, 20], ["pigs", "SPECIES", 146, 150], ["Five uninfected pigs", "TREATMENT", 0, 20], ["the same method", "TREATMENT", 114, 129], ["uninfected", "OBSERVATION_MODIFIER", 5, 15], ["pigs", "OBSERVATION", 16, 20], ["nostril", "ANATOMY", 99, 106], ["infected pigs", "OBSERVATION", 137, 150]]], ["Three infected pigs from each group were removed to a separate room with three na\u00efve pigs at 2 days post-inoculation (dpi).", [["pigs", "ORGANISM", 15, 19], ["pigs", "ORGANISM", 85, 89], ["pigs", "SPECIES", 15, 19], ["pigs", "SPECIES", 85, 89], ["pigs", "SPECIES", 15, 19], ["pigs", "SPECIES", 85, 89], ["three na\u00efve pigs", "TREATMENT", 73, 89], ["infected", "OBSERVATION_MODIFIER", 6, 14], ["pigs", "OBSERVATION", 15, 19]]], ["Clinical signs were observed by veterinary inspections at a fixed time daily throughout the duration of the study (14 days).", [["Clinical signs", "TEST", 0, 14], ["the study", "TEST", 104, 113]]], ["Nasal washes were collected from all pigs at 3, 5, 7, and 9 dpi.", [["Nasal", "ANATOMY", 0, 5], ["pigs", "ORGANISM", 37, 41], ["pigs", "SPECIES", 37, 41], ["Nasal washes", "TREATMENT", 0, 12], ["washes", "OBSERVATION", 6, 12]]], ["At 3 and 5 dpi, three pigs from each infection group and one pig from control group were anesthetized and their nasal turbinates, tracheas, and lungs were collected for virus titration.Microscopical examination of lungs ::: Materials and MethodsThe lung tissues collected at 5dpi were fixed in 10% phosphate-buffered formalin for histopathological examination which was performed as described previously373839.", [["nasal turbinates", "ANATOMY", 112, 128], ["tracheas", "ANATOMY", 130, 138], ["lungs", "ANATOMY", 144, 149], ["lungs", "ANATOMY", 214, 219], ["lung tissues", "ANATOMY", 249, 261], ["infection", "DISEASE", 37, 46], ["phosphate", "CHEMICAL", 298, 307], ["phosphate", "CHEMICAL", 298, 307], ["formalin", "CHEMICAL", 317, 325], ["pigs", "ORGANISM", 22, 26], ["pig", "ORGANISM", 61, 64], ["nasal turbinates", "MULTI-TISSUE_STRUCTURE", 112, 128], ["tracheas", "MULTI-TISSUE_STRUCTURE", 130, 138], ["lungs", "ORGAN", 144, 149], ["lungs", "ORGAN", 214, 219], ["lung tissues", "TISSUE", 249, 261], ["phosphate-buffered formalin", "SIMPLE_CHEMICAL", 298, 325], ["pigs", "SPECIES", 22, 26], ["pig", "SPECIES", 61, 64], ["pigs", "SPECIES", 22, 26], ["pig", "SPECIES", 61, 64], ["each infection group", "TREATMENT", 32, 52], ["virus titration", "TREATMENT", 169, 184], ["Microscopical examination", "TEST", 185, 210], ["histopathological examination", "TEST", 330, 359], ["infection", "OBSERVATION", 37, 46], ["nasal turbinates", "ANATOMY", 112, 128], ["tracheas", "ANATOMY", 130, 138], ["lungs", "ANATOMY", 144, 149], ["lungs", "ANATOMY", 214, 219], ["lung tissues", "ANATOMY", 249, 261]]], ["Briefly, samples were processed for paraffin embedding and cut into 5-\u03bcm-thick sections.", [["samples", "ANATOMY", 9, 16], ["sections", "ANATOMY", 79, 87], ["paraffin", "CHEMICAL", 36, 44], ["paraffin embedding", "TREATMENT", 36, 54]]], ["One section from each tissue sample was stained with hematoxylin and eosin (H&E) stain.", [["tissue sample", "ANATOMY", 22, 35], ["hematoxylin", "CHEMICAL", 53, 64], ["eosin", "CHEMICAL", 69, 74], ["tissue", "TISSUE", 22, 28], ["hematoxylin", "SIMPLE_CHEMICAL", 53, 64], ["eosin", "SIMPLE_CHEMICAL", 69, 74], ["hematoxylin", "TREATMENT", 53, 64], ["eosin (H&E) stain", "TEST", 69, 86]]], ["Another section was processed for immunohistological staining with a rabbit polyclonal antibody (orb176401; Biorbyt, USA) against influenza A virus NP.", [["influenza A virus", "DISEASE", 130, 147], ["rabbit", "ORGANISM", 69, 75], ["influenza A virus NP", "ORGANISM", 130, 150], ["rabbit polyclonal antibody", "PROTEIN", 69, 95], ["rabbit", "SPECIES", 69, 75], ["influenza A virus", "SPECIES", 130, 147], ["rabbit", "SPECIES", 69, 75], ["influenza A virus", "SPECIES", 130, 147], ["Another section", "TEST", 0, 15], ["immunohistological staining", "TEST", 34, 61], ["a rabbit polyclonal antibody", "TEST", 67, 95], ["influenza", "PROBLEM", 130, 139]]], ["Specific antigen-antibody reactions were visualized by using DAB Detection Kit (Polymer) (ORIGENE, Wuxi, China) and counterstained with hematoxylin.Microscopical examination of lungs ::: Materials and MethodsThe severity of microscopic lung lesions was scored by the distribution or by the extent of lesions within the sections examined as follows: 0, no visible changes; 1, mild focal or multifocal change; 2, moderate multifocal change; 3, moderate diffuse change; and 4, severe diffuse change40.", [["lungs", "ANATOMY", 177, 182], ["lung lesions", "ANATOMY", 236, 248], ["lesions", "ANATOMY", 300, 307], ["sections", "ANATOMY", 319, 327], ["hematoxylin", "CHEMICAL", 136, 147], ["DAB", "SIMPLE_CHEMICAL", 61, 64], ["hematoxylin", "SIMPLE_CHEMICAL", 136, 147], ["lungs", "ORGAN", 177, 182], ["lung lesions", "PATHOLOGICAL_FORMATION", 236, 248], ["lesions", "PATHOLOGICAL_FORMATION", 300, 307], ["Specific antigen", "TEST", 0, 16], ["antibody reactions", "PROBLEM", 17, 35], ["hematoxylin", "TREATMENT", 136, 147], ["Microscopical examination", "TEST", 148, 173], ["Methods", "TREATMENT", 201, 208], ["microscopic lung lesions", "PROBLEM", 224, 248], ["lesions", "PROBLEM", 300, 307], ["the sections", "TEST", 315, 327], ["visible changes", "PROBLEM", 355, 370], ["mild focal or multifocal change", "PROBLEM", 375, 406], ["moderate multifocal change", "PROBLEM", 411, 437], ["moderate diffuse change", "PROBLEM", 442, 465], ["severe diffuse change40", "PROBLEM", 474, 497], ["lungs", "ANATOMY", 177, 182], ["severity", "OBSERVATION_MODIFIER", 212, 220], ["microscopic", "OBSERVATION_MODIFIER", 224, 235], ["lung", "ANATOMY", 236, 240], ["lesions", "OBSERVATION", 241, 248], ["distribution", "OBSERVATION_MODIFIER", 267, 279], ["extent", "OBSERVATION_MODIFIER", 290, 296], ["lesions", "OBSERVATION", 300, 307], ["no", "UNCERTAINTY", 352, 354], ["visible", "OBSERVATION_MODIFIER", 355, 362], ["changes", "OBSERVATION", 363, 370], ["mild", "OBSERVATION_MODIFIER", 375, 379], ["focal", "OBSERVATION_MODIFIER", 380, 385], ["multifocal", "OBSERVATION_MODIFIER", 389, 399], ["change", "OBSERVATION", 400, 406], ["moderate", "OBSERVATION_MODIFIER", 411, 419], ["multifocal", "OBSERVATION_MODIFIER", 420, 430], ["change", "OBSERVATION", 431, 437], ["moderate", "OBSERVATION_MODIFIER", 442, 450], ["diffuse", "OBSERVATION_MODIFIER", 451, 458], ["change", "OBSERVATION", 459, 465], ["severe", "OBSERVATION_MODIFIER", 474, 480], ["diffuse", "OBSERVATION_MODIFIER", 481, 488], ["change40", "OBSERVATION", 489, 497]]], ["The detection of swine influenza antigen in lung was executed through a ranked sore of 0\u20134, which was used to evaluate the number of positive cells per section taken from each block, as previously described41.", [["lung", "ANATOMY", 44, 48], ["cells", "ANATOMY", 142, 147], ["swine", "ORGANISM", 17, 22], ["lung", "ORGAN", 44, 48], ["cells", "CELL", 142, 147], ["swine influenza antigen", "PROTEIN", 17, 40], ["positive cells", "CELL_TYPE", 133, 147], ["swine", "SPECIES", 17, 22], ["swine", "SPECIES", 17, 22], ["swine influenza antigen in lung", "PROBLEM", 17, 48], ["positive cells", "PROBLEM", 133, 147], ["swine", "OBSERVATION_MODIFIER", 17, 22], ["influenza", "OBSERVATION", 23, 32], ["lung", "ANATOMY", 44, 48], ["positive cells", "OBSERVATION", 133, 147]]], ["The indication of the scores was as follows: 0, no SIV-antigen-positive cells; 1, 1\u201310 positive cells; 2, 11\u201330 positive cells; 3, 31\u2013100 positive cells; and 4, = or > 100 positive cells.", [["cells", "ANATOMY", 72, 77], ["cells", "ANATOMY", 96, 101], ["cells", "ANATOMY", 121, 126], ["cells", "ANATOMY", 147, 152], ["cells", "ANATOMY", 181, 186], ["SIV", "ORGANISM", 51, 54], ["cells", "CELL", 96, 101], ["cells", "CELL", 121, 126], ["cells", "CELL", 147, 152], ["cells", "CELL", 181, 186], ["the scores", "TEST", 18, 28], ["SIV-antigen", "TEST", 51, 62], ["positive cells", "PROBLEM", 63, 77], ["positive cells", "TEST", 138, 152], ["positive cells", "OBSERVATION", 63, 77], ["positive cells", "OBSERVATION", 172, 186]]], ["Two independent pathologists scored all lungs and slides from blinded experimental groups.Quantitative real-time PCR (qRT- PCR) ::: Materials and MethodsTotal RNA in PAM cells or lung homogenates were extracted using TRIzol reagent at specified time points according to the manufacturer\u2019s instructions (Invitrogen).", [["lungs", "ANATOMY", 40, 45], ["PAM cells", "ANATOMY", 166, 175], ["lung homogenates", "ANATOMY", 179, 195], ["lungs", "ORGAN", 40, 45], ["PAM cells", "CELL", 166, 175], ["lung homogenates", "CANCER", 179, 195], ["MethodsTotal RNA", "RNA", 146, 162], ["PAM cells", "CELL_LINE", 166, 175], ["Quantitative real-time PCR", "TEST", 90, 116], ["qRT", "TEST", 118, 121], ["Materials", "TREATMENT", 132, 141], ["MethodsTotal RNA in PAM cells", "TREATMENT", 146, 175], ["lung homogenates", "PROBLEM", 179, 195], ["TRIzol reagent", "TREATMENT", 217, 231], ["lungs", "ANATOMY", 40, 45], ["PAM cells", "OBSERVATION", 166, 175], ["lung", "ANATOMY", 179, 183]]], ["Oligo-(dT) primed cDNA was generated from 1 \u03bcg of total RNA per sample using Superscript III First-Strand Synthesis SuperMix (Invitrogen).", [["Oligo", "CHEMICAL", 0, 5], ["Oligo-(dT) primed cDNA", "DNA", 0, 22], ["Oligo-(dT) primed cDNA", "TEST", 0, 22], ["total RNA", "TREATMENT", 50, 59], ["Superscript III", "TREATMENT", 77, 92], ["Strand Synthesis SuperMix (Invitrogen)", "TREATMENT", 99, 137]]], ["The qRT-PCR mixture for each sample consisted of 10 \u03bcl 2 \u00d7 SYBR green PCR master mix (Applied Biosystems), 7 \u03bcl of nuclease-free water, 0.5 \u03bcl of each primer, and 2 \u03bcl of cDNA template.", [["sample", "ANATOMY", 29, 35], ["nuclease", "PROTEIN", 115, 123], ["cDNA template", "DNA", 171, 184], ["The qRT-PCR mixture", "TREATMENT", 0, 19], ["each sample", "TEST", 24, 35], ["nuclease-free water", "TREATMENT", 115, 134], ["each primer", "TREATMENT", 146, 157], ["cDNA template", "TREATMENT", 171, 184]]], ["Expression values for each gene, relative to RPL4, were calculated using the 2\u2212\u25b3\u25b3CT method.", [["RPL4", "GENE_OR_GENE_PRODUCT", 45, 49], ["RPL4", "DNA", 45, 49], ["Expression values", "TEST", 0, 17], ["the 2\u2212\u25b3\u25b3CT method", "TREATMENT", 73, 90]]], ["Primers for qRT-PCR analysis of pig IFN-\u03b1/\u03b2 are listed as following: IFN-\u03b1, Forward, 5\u2032-GCCTCCTGCACCAGTTCTACA-3\u2032, Reverse, 5\u2032-TGCATGACACAGGCTTCCA-3\u2032; IFN-\u03b2, Forward, 5\u2032-TGCAACCACCACAATTCC-3\u2032, Reverse, 5\u2032-CTGAGAATGCCGAAGATCTG-3\u2032.Interferon-\u03b2 reporter assay ::: Materials and MethodsTo measure the IFN-I shutoff function of PA-X, a luciferase based, Sendai virus-mediated IFN-\u03b2 promoter activation assay was conducted as previously described13.", [["pig", "ORGANISM", 32, 35], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 36, 41], ["\u03b2", "GENE_OR_GENE_PRODUCT", 42, 43], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 69, 74], ["5\u2032-TGCATGACACAGGCTTCCA-3\u2032", "SIMPLE_CHEMICAL", 123, 148], ["IFN-\u03b2", "SIMPLE_CHEMICAL", 150, 155], ["Interferon-\u03b2", "GENE_OR_GENE_PRODUCT", 228, 240], ["IFN-I", "GENE_OR_GENE_PRODUCT", 296, 301], ["PA-X", "GENE_OR_GENE_PRODUCT", 322, 326], ["luciferase", "GENE_OR_GENE_PRODUCT", 330, 340], ["Sendai virus", "ORGANISM", 348, 360], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 370, 375], ["IFN", "PROTEIN", 36, 39], ["\u03b1", "PROTEIN", 40, 41], ["\u03b2", "PROTEIN", 42, 43], ["IFN", "PROTEIN", 69, 72], ["\u03b1", "PROTEIN", 73, 74], ["IFN", "PROTEIN", 150, 153], ["\u03b2", "DNA", 154, 155], ["IFN", "PROTEIN", 296, 299], ["X", "DNA", 325, 326], ["luciferase", "PROTEIN", 330, 340], ["IFN", "PROTEIN", 370, 373], ["\u03b2 promoter", "DNA", 374, 384], ["pig", "SPECIES", 32, 35], ["pig", "SPECIES", 32, 35], ["Sendai virus", "SPECIES", 348, 360], ["qRT", "TEST", 12, 15], ["PCR analysis", "TEST", 16, 28], ["pig IFN", "TREATMENT", 32, 39], ["IFN", "TEST", 69, 72], ["Forward", "TEST", 76, 83], ["GCCTCCTGCACCAGTTCTACA", "TEST", 88, 109], ["TGCATGACACAGGCTTCCA", "TEST", 126, 145], ["IFN", "TEST", 150, 153], ["Forward", "TEST", 157, 164], ["TGCAACCACCACAATTCC", "TEST", 169, 187], ["CTGAGAATGCCGAAGATCTG", "TEST", 204, 224], ["Methods", "TREATMENT", 274, 281], ["the IFN", "TREATMENT", 292, 299], ["PA", "TEST", 322, 324], ["a luciferase", "TEST", 328, 340], ["Sendai virus-mediated IFN", "TREATMENT", 348, 373], ["promoter activation assay", "TEST", 376, 401]]], ["Briefly, 293T cells in 24-well plates were transfected with 500 ng of empty vector or different PA-X proteins respectively.", [["293T cells", "ANATOMY", 9, 19], ["293T cells", "CELL", 9, 19], ["PA-X proteins", "GENE_OR_GENE_PRODUCT", 96, 109], ["293T cells", "CELL_LINE", 9, 19], ["PA-X proteins", "PROTEIN", 96, 109], ["empty vector", "TREATMENT", 70, 82]]], ["Additionally, 200 ng of an IFN-\u03b2-promoter-luciferase reporter plasmid (pIFNbLuc) and 20 ng of a plasmid constitutively expressing Renilla luciferase (pRL-TK from Promega) were transfected.", [["plasmid", "ANATOMY", 96, 103], ["IFN-\u03b2-", "GENE_OR_GENE_PRODUCT", 27, 33], ["luciferase", "GENE_OR_GENE_PRODUCT", 42, 52], ["luciferase", "GENE_OR_GENE_PRODUCT", 138, 148], ["pRL-TK", "GENE_OR_GENE_PRODUCT", 150, 156], ["Promega", "GENE_OR_GENE_PRODUCT", 162, 169], ["IFN-\u03b2-promoter", "DNA", 27, 41], ["luciferase reporter plasmid", "DNA", 42, 69], ["pIFNbLuc", "DNA", 71, 79], ["plasmid", "DNA", 96, 103], ["Renilla luciferase", "DNA", 130, 148], ["pRL", "PROTEIN", 150, 153], ["TK", "PROTEIN", 154, 156], ["an IFN-\u03b2-promoter-luciferase reporter plasmid (pIFNbLuc)", "TREATMENT", 24, 80], ["a plasmid", "TREATMENT", 94, 103], ["Renilla luciferase", "TEST", 130, 148], ["pRL", "TEST", 150, 153], ["Renilla luciferase", "OBSERVATION", 130, 148]]], ["At 18 hours post transfection, cells were infected with Sendai virus to induce the IFN-\u03b2 promoter at a MOI of 5.0.", [["cells", "ANATOMY", 31, 36], ["cells", "CELL", 31, 36], ["Sendai virus", "ORGANISM", 56, 68], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 83, 88], ["IFN-\u03b2 promoter", "DNA", 83, 97], ["Sendai virus", "SPECIES", 56, 68], ["Sendai virus", "PROBLEM", 56, 68], ["a MOI", "TEST", 101, 106]]], ["At 18 hour post virus inoculation, cell lysate was prepared with Dual-Luciferase Reporter Assay System (Promega, USA) and luciferase activity was measured using GloMax 96 microplate luminometer (Promega, USA).", [["cell lysate", "ANATOMY", 35, 46], ["cell lysate", "CELL", 35, 46], ["luciferase", "GENE_OR_GENE_PRODUCT", 122, 132], ["luciferase", "PROTEIN", 122, 132], ["virus inoculation", "TREATMENT", 16, 33], ["cell lysate", "TREATMENT", 35, 46], ["Dual-Luciferase", "TREATMENT", 65, 80], ["luciferase activity", "TEST", 122, 141], ["GloMax", "TREATMENT", 161, 167]]], ["The relative luciferase activity of the group with the empty vector was set as 100%, and the other groups were presented relative to that.Statistical analyses ::: Materials and MethodsAll statistical analyses were performed using GraphPad Prism Software Version 5.00 (GraphPad Software Inc., San Diego, CA, USA).", [["luciferase", "GENE_OR_GENE_PRODUCT", 13, 23], ["luciferase", "PROTEIN", 13, 23], ["empty vector", "DNA", 55, 67], ["the empty vector", "TREATMENT", 51, 67], ["All statistical analyses", "TEST", 184, 208], ["luciferase activity", "OBSERVATION", 13, 32]]], ["Statistically significant differences between experimental groups were determined using the analysis of variance (ANOVA) method.", [["the analysis", "TEST", 88, 100], ["significant", "OBSERVATION_MODIFIER", 14, 25]]], ["Differences were considered statistically significant at P < 0.05.Additional InformationHow to cite this article: Xu, G. et al. Truncation of C-terminal 20 amino acids in PA-X contributes to adaptation of swine influenza virus in pigs.", [["amino acids", "CHEMICAL", 156, 167], ["swine influenza virus", "DISEASE", 205, 226], ["C", "CHEMICAL", 142, 143], ["amino acids", "CHEMICAL", 156, 167], ["amino acids", "AMINO_ACID", 156, 167], ["PA-X", "GENE_OR_GENE_PRODUCT", 171, 175], ["swine influenza virus", "ORGANISM", 205, 226], ["pigs", "ORGANISM", 230, 234], ["C-terminal 20 amino acids", "PROTEIN", 142, 167], ["PA-X", "PROTEIN", 171, 175], ["swine influenza virus", "SPECIES", 205, 226], ["pigs", "SPECIES", 230, 234], ["swine influenza virus", "SPECIES", 205, 226], ["pigs", "SPECIES", 230, 234], ["Truncation of C-terminal 20 amino acids", "PROBLEM", 128, 167], ["swine influenza virus", "PROBLEM", 205, 226], ["influenza virus", "OBSERVATION", 211, 226]]], ["Rep.6, 21845; doi: 10.1038/srep21845 (2016).", [["Rep.6, 21845", "CHEMICAL", 0, 12]]]]}